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Introduction
In the last decades, enormous efforts have been pushed toward the development of
therapeutic approaches for human genetic diseases, and the research all over the
world has obtained remarkable achievements. Advances in biotechnology have
brought gene therapy to the forefront of medical research. Gene replacement, in
which a normal copy of the defective gene is efficiently delivered and expressed
into target cells, represents one of the most advanced strategies that produced
encouraging results in patients with diseases caused by single gene recessive dis-
orders (like haemophilia, muscular dystrophy, sickle cell anemia, cystic fibrosis
etc.), some viral infections and inherited genetic diseases such as cancer and ADA
deficiency [13]. Notwithstanding, the intense research also led to potential ther-
apeutic strategies based on the correction of the specific disease-causing defects,
which might circumvent some limitations (i.e. gene size, gene regulation) of gene
replacement therapy. These approaches are of great interest for patients with
coagulation deficiencies, since they would benefit from even small increase in
functional protein levels. The low therapeutic threshold makes the rare bleeding
disorders (RBDs) an ideal target for investigating therapeutic strategies based
on counteracting the pathogenic molecular mechanisms. This work propose the
development of in–vitro and in–vivo models of RBDs in order to explore correc-
tive molecular approaches acting on the specific disease-causing defects, both at
transcriptional and post-transcriptional level.
The chapter 1 describes the usage of engineered transcription factors (eTFs)
as potential therapeutic strategy for FVII deficiency caused by promoter muta-
tions. Transcription impairment by mutations in the promoter regions represents
indeed a small, but considerable cause of severe coagulation factor defects and
of all inherited human diseases. These mutations often affect only the untrans-
lated control regions impairing to different extent the expression of completely
unaffected genes. Different from gene therapy approaches inserting exogenous
sequences that drive the expression of the missing factor, the induced restart of
the transcription would maintain the natural chromosomal structure and context
restoring gene expression. Engineered TFs have been shown to have wide-range
potential in modulating desired gene expression through targeting their promot-
ers [109]. A recent breakthrough with transcription activator-like effector proteins
(TALEs) makes it possible to establish universal types of engineered TFs that can
potentially target any selected gene. Hence, fusion of a TALE-derived binding
domain to a transcriptional activator, such as VP64 [21], could generate TALE-
transcription factors (TALE-TFs) that can target selected promoter regions and
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modulate expression of corresponding genes [55]. Intensive studies on stem-cell
maintenance and differentiation have been recently carried out with TALE-TFs
[55, 27, 46, 56, 72], but to our knowledge only one example of these eTFs has
been used for the recovery of transcription impaired by human disease-causing
mutations [86]. As a model to exploit TALE-TF transcription restoration in
coagulation factor deficiencies, we chose two severe promoter mutations impair-
ing FVII transcription, the -94 C>G and -61 T>G transversions, falling in the
binding site for the hepato-specific HNF-4 and the ubiquitous Sp1 transcription
factors, respectively [18, 29]. The patients homozygous for these mutations expe-
rience life-threatening hemorrhagic symptoms and require replacement therapy.
Through the expression of gene reporter plasmids we first created a cellular model
for the two F7 promoter variants. Then, we assembled 4 TALE-TFs (TF1-4) de-
signed to target different regions on the F7 proximal promoter in order to test
their efficacy in stimulating transcriptional activity on the target gene. The treat-
ment with the different TALE-TFs demonstrated that TF4, targeting a sequence
between the mutations, induced a robust increase of gene transcription in the
presence of the defective promoter. Interestingly, TF4 appreciably increased the
endogenous F7 transcription and mRNA levels in HepG2 cells and induced F7
expression in Hek293 cells that do not virtually express FVII.
The chapter 2 describes the exploitation of the Sleeping Beauty Transpo-
son System (SBTS) to develop cellular and mouse model of haemophilia B (HB)
caused by splicing mutations, in order to assess the efficacy of an RNA-based ther-
apeutic approach. HB is a prototypical example of disease with a heterogeneous
mutational pattern (www.factorix.org) and a relatively high frequency of splicing
mutations (>15%) in severe disease forms. Intervention at the pre-mRNA splic-
ing level is emerging as a promising therapeutic strategy for genetic disorders.
Increasing attention has been given to the U1 small nuclear RNA (U1snRNA)
that, in the earliest splicing step, mediates the recognition of the donor splice site
(5’ss) by the ribonucleoprotein U1snRNP. Studies in various cellular models of
human disease indicated the potential therapeutic effect of engineered U1snRNAs
to rescue aberrant splicing caused by mutations at 5’ss, a relatively frequent cause
of severe forms. In the last years, modified U1snRNAs have been exploited to
correct splicing mutations causing severe coagulation factor VII deficiency and
HB [37, 74, 75]. The rescue has been proven in cellular models by using F7/F9
minigenes. However, the F9 mutational pattern is extremely heterogeneous, with
several different splicing mutations. Therefore, the evaluation of the U1snRNA-
mediated correction strategy in–vivo implies the creation of mouse models, which
are not yet available. Here we used the SBTS to develop cellular/mouse models
of HB caused by the FIXex5-2C splicing variant, and subsequently assess the
U1-mediated correction in chromatin context. Indeed, in contrast to other ap-
proaches the transposon enables the transgene to be integrated into the genome,
which represents the preferred physiologic situation for subsequent splicing stud-
ies. Initially we have performed experiments to test the hyperactive transposase
SB100X-mediated integration of the splicing-competent human FIX transgene
into the genome using human embryonic kidney cells. We have generated Hek293
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stable clones expressing the normal or mutated human splicing-competent FIX
cassettes integrated into the genome as a result of the transposase activity. These
preliminary studies provided us with optimized experimental protocol to create in
a relatively short time cellular models of human disease caused by splicing muta-
tions. Moreover, it permitted the assessment of the modified U1 snRNA-mediated
rescue in–vitro in a genomic expression context instead of a transient episomal
system. This also provided with the rationale for the creation of mouse mod-
els through hydrodynamic injection of the transposon plasmids and of SB100X
transposase in C57BL/6 wt mice [62] in order to assess the efficacy of the U1
snRNAs-mediated rescue in–vivo.
viii Introduction
Chapter 1
TALE TFs
1.1 Brief overview of coagulation process
Haemostasis is a physiological process that depicts a delicate balance between
pro-coagulant and anti-coagulant activities. From many years researchers have
been interested in deepening the mechanisms underlying the complex series of
biochemical reactions occurring to maintain these equilibrium in-vivo. According
to the classical coagulation waterfall/cascade model, described in 1964 by two
independent groups [96, 112], several proteins with serine-protease activity are
involved in the formation of blood clot whenever an injury in a vessel occurs. In
physiological conditions these coagulation factors, circulating normally as zymo-
gens, are converted by cleavage into their active form and interact both together
and with the pro-coagulant surfaces in order to produce the fibrin formation [95].
In this traditional view a contact pathway (intrinsic) as well as a tissue-factor
(TF) depending-pathway (extrinsic) have been described. The intrinsic pathway,
so named because triggered by components already present in blood, is composed
of FXII and pre-kallikrein (PK), with FXII being activated either by PK or plas-
min to the active enzyme (FXIIa) when in contact with a negatively charged or
artificial surfaces. In the intrinsic pathway the activation of a certain amount of
FXII leads to the subsequent generation of FXIa from FXI, which then activates
FIX. FIXa, together with phospholipids, calcium and FVIIIa, activates FX, which
in turn converts prothrombin (FII) to thrombin (FIIa). A peculiar feature of FXII
and PK zymogens is that they are calcium-independent, thereby able to “auto-
activate” in a continuous manner even in the presence of anticoagulant molecules.
In spite of this, it has been reported that individuals with deficiencies of FXII or
PK do not experience any bleeding tendency in vivo, thereby suggesting that the
contact pathway may not have such a fundamental role in blood coagulation, but
rather in the thrombus formation [10, 97]. The first waterfall/cascade model has
been implemented from the 1977, with the work of Osterud and Rapaport showing
that FVIIa-TF can activate FIX and FX, so focusing attention on the role of the
extrinsic pathway in interacting with the intrinsic one during clotting [3]. And in
1992 a group proposed the actual model of coagulation, called “cell-based” [105],
which is composed of an initiation phase and a propagation phase (fig.1.1). The
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clotting is triggered in the initiation phase when tissue factor (TF), also called
thromboplastin or FIII, comes in contact with blood. TF is an integral membrane
protein expressed on the surface of several cell types, like adventitial cell, smooth
muscle cells and keratinocytes, that normally are not in contact with blood flow.
When a lesion in the endothelial barrier occurs these cells become exposed to
blood and consequently TF is able to bind the plasma serine protease FVIIa,
forming a complex that is able to generate a modest amount of thrombin. In the
following propagation phase, acting on the activated platelet surfaces, the tenase
complex can be properly assembled together with the prothrombinase complex
and calcium for massive production of thrombin. This “thrombin burst” arises
at the end in the conversion of insoluble fibrinogen into soluble fibrin monomers
forming the stable clot.
Figure 1.1: Cell-based model of coagulation
1.1.1 Initiation-FVII/FVIIa
Factor VII is a vitamin K-dependent serine protease produced in liver and circu-
lating at a concentration of 500 ng/ml [33, 90]. It displays the shortest half-life
as zymogen (approximately 5 hours) and is the only coagulation factor that is
present in both the active and inactive forms. In humans, the active form (FVIIa)
represents about 1% of total circulating FVII. FVII itself has a negligible activity
and participates in the initiation phase principally after its activation to FVIIa. A
number of coagulation enzymes including FIXa, FXa, FXIIa, thrombin, plasmin
or FVII-activating proteases can activate FVII. However, FXa seems to be the
most potent activator of FVII. Also FIX plays an important role in this activation
because humans with haemophilia B display very low levels of FVIIa. Moreover,
the FVII-TF complex can be auto-activated by FVIIa-TF complex. FVIIa has
a long half-life in plasma because unless it is bound to TF it can not be inacti-
vated by any protease inhibitor. The FVIIa-TF complex then activates FIX to
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FIXa and FX to FXa. It is worth noting that this initiation phase only results
in a trace amount of thrombin after FXa activation, because FXa and thrombin
are rapidly neutralized by antithrombin (AT) and the complex FVIIa-TF-FXa
by the tissue factor pathway inhibitor (TFPI). The TFPI/AT provides a good
regulatory system in order to prevent a massive thrombin generation for a false
alarm. The pro-coagulant signal is provided only when TF is exposed at high
enough levels to overcome inhibition by TFPI an AT. If this is the case, thrombin
is able to enhance its own generation through the activation of FXI to FXIa and
FV to FVa on the platelets surface, and also through the activation of FVIII to
FVIIIa by cleaving von Willebrand factor (vWF). In this context recruited acti-
vated platelets provide the pro-coagulant phospholipids membrane needed for the
subsequent enzymatic reactions, and the further generation of FXa is dependent
on the formation of the tenase complex.
1.1.2 Propagation–The tenase complex
Once FX, FIX and the cofactors FV and FVIII are activated after the generation
of thrombin in the initiation phase the assembly of tenase complex can occurs.
FIXa, in association with its cofactor FVIIIa, binds FX and calcium on negatively
charged surfaces, mostly on platelets membrane, in order to form the tenase
complex, leading to the generation of a large amount of FXa. Most of the FXa is
physiologically produced in vivo by the tenase complex, which is considered to be
around 50-fold more efficient in this process compared to the FVIIa-TF complex.
Therefore, in the initiation phase the amount of FXa is insufficient to sustain
hemostasis whereas during propagation a massive production of FXa is achieved
through the formation of the tenase complex. FXa participates in the assembly
of the prothrombinase complex together with FVa and calcium, which results in
an explosive generation of thrombin and the subsequent stable clot formation.
In physiological conditions the process is tightly controlled, in order to maintain
the coagulative events just at the site of injury. As a matter of fact even if
thrombin and FXa can diffuse from the site of damage to the adjacent healthy
endothelium they are inhibited by the lack of pro-coagulant membranes and the
presence of anticoagulants molecules like AT, TFPI and thrombomodulin, able to
reduce their activity. It is worth noting that in the propagation phase both FVIII
and FIX are required. Indeed, in the absence of FVIII and FIX the initiation
occurs normally, but the propagation steps are severely diminished, resulting in
a deficient fibrin clot formation and the incapacity of the hemostatic system to
respond in repairing the damaged tissues.
1.2 Focus on FVII: gene and protein features
1.2.1 Factor FVII protein
Human factor FVII is a zymogen for a vitamin K-dependent serine protease syn-
thesized in liver and circulating in plasma at a concentration of approximately
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0.5µg/ml (10nmol/L). It is secreted into blood as a single chain glycoprotein of
48KDa. All vitamin K-dependent coagulation zymogens share a similar protein
domain structure consisting an N-terminal gamma-carboxyglutamic acid-rich do-
main (Gla domain, residues 1-38), a short hydrophobic segment (residues 39-45)
that often is considered as part of the Gla domain, two epidermal growth fac-
tor (EGF)-like domains (residues 47-84 and 85-131), and the C-terminal serine
protease domain (residues 153-406). The Gla domain is responsible for the in-
teraction of the protein with lipid membranes, while the EGF-like domain has a
calcium ion binding site that to some degree mediates interaction with the TF
exposed at the site of vessel injury (Tab 1.1). The major proportion of FVII
Table 1.1: Summary of factor VII features
circulates in plasma in the inactive form. Activation of FVII occurs by the cleav-
age of a single peptide bond between Arg152 and Ile153, located in the region
connecting the second EGF-like domain and the protease domain [111]. This
results in the formation of a two-chain FVIIa molecule consisting of a light chain
of 152 amino acids (containing the membrane-binding Gla domain) and a heavy
chain of 254 amino acids (containing the catalytic domain) held together by a
single disulfide bond (between Cys-135 and Cys-262). Conversion of factor VII
to factor VIIa is catalyzed by a number of proteases, including thrombin, factor
IXa, factor Xa, factor XIa, and factor XIIa [111]. Comparison of these proteins
has shown that factor Xa, in association with phospholipids, has the highest po-
tential to activate factor VII. Rapid activation also occurs when factor VII is
combined with its cofactor, which is the tissue factor in the presence of calcium
(autocatalysis). This reaction may be initiated by a small amount of preexisting
factor VIIa. FVIIa is a trypsin-like enzyme and catalyses the hydrolysis of pep-
tide bonds within a polypeptide chain to produce two new smaller peptides. In
1964, FVIIa proteolytic activity was observed first against FX, but the methods
used did not reveal whether TF first reacted with FVII to form an intermedi-
ate that then activated FX or whether FVII directly activated FX. A few years
later, it was demonstrated that TF interacted with FVII and the formed inter-
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mediate was catalytically active [122]. The reaction product of TF and FVII is
a potent activator of FX and also of FIX [3]. The interaction of FVIIa with TF
is Ca2+–dependent. Ca2+ saturation of the Gla domain is likely responsible for
this increase in affinity, since deletion of Gla in FVIIa results in a loss of affinity
for TF. Ca2+ may stabilize energetically important hydrophobic contacts of Gla
with TF [7]. In addition, Ca2+ increases FVIIa affinity for FX by conformational
changes in FVIIa and FX that are essential for the interaction of these proteins
with phospholipids [120].
1.3 Factor FVII gene
The human factor VII gene (F7) is a single copy gene located on chromosome
13 (13q34) which consists of eight exons spread over 12 kb of genomic DNA and
produces a 2.4-kb mRNA encoding a secreted protein of 406 amino acids. The
entire nucleotide sequence was reported for the first time in 1987 [70]. The introns
ranged in size from 68 nucleotides (intron C) to nearly 2.6 kb (intron A). The
exons also varied considerably in size, ranging from 25 nucleotides (exon 3) to
1.6 kb (exon 8). In 1986 different cDNAs coding for factor VII were isolated
from a cDNA library prepared from a HepG2 cell line [45], by which it was
possible to establish that 1b is an optional exon not always included in the mature
mRNA. Its inclusion determines the length of the pre-pro leader sequence (from 38
Table 1.2: Factor VII gene exons organization
aminoacids when the mRNA lack 1b to 60 aminoacids when 1b is incorporated).
In both cases the product is an in frame-mRNA that results in a functional
transcript that codes for a biologically active FVII. In normal liver the most
represented form is mRNA lacking exon 1b. As for other coagulation factor genes,
F7 exons encode for discrete domains of the protein (Tab. 1.2): the pre-pro leader
sequence (exon 1a, 1b and part of exon 2), the γ–carboxilase region (exons 2 and
3), the two EGF-like domains (exons 4 and 5), the activation domain (exon 6)and
finally the catalytic domain (exons 7 and 8). The conservation of domains, exons
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and introns positions among the members of the vitamin K-dependent protein
family supports the theory of their evolution as modular protein by exon shuffling
[100].
1.4 FVII deficiency
FVII, or proconvertin, deficiency was first recognized in 1951 [16]. Considered
the most common of rare bleeding disorders its incidence is estimated at 1 per
300,000–500,000 [59]. It is inherited in an autosomal recessive fashion and affects
males and females equally. Factor VII deficiency is very rare, but like all auto-
somal recessive disorders, it is found more frequently in areas of the world where
marriage between close relatives is common. Studies conducted on F7 knock-
out mice suggest that a complete lack of FVII is incompatible with life [77], so
it is thought that FVII deficiency can not be associated with complete absence
of functional FVII. Triplett et al. [87] have classified FVII deficiency in CRM-
(activity and antigen proportionally reduced), CRM+ (reduced activity, antigen
normal) and CRMred (antigen is reduced but not as much as activity). This
haemorragic disorder displays a variable clinical heterogeneity [65], which ranges
from lethal to mild or even asymptomatic forms (in general when FVII:C >10%).
The most frequent symptoms, like epistaxis and early bruising, indicate that the
disease is mild in the majority of cases. However, severe to very severe cases are
not infrequent, and are characterized by hemartrosis, muscle hematomas, or even
central nervous system (CNS) and gastrointestinal (GI) bleeding. Nose bleeding
is by far the most frequent symptom and is not gender-related. Other very com-
mon symptoms are post–operative, skin and gum bleeds. As for gender, women
are more prevalent among bleeders: this is mainly attributable to menorrhagia,
which occurs in about two-thirds of women of fertile age but gum bleeding and
easy bruising are also more frequent in females. Severe and life-threatening haem-
orrhages are rare in general (about 5% of the bleeds) and occur most frequently
during the first 6 months of life. In newborns (< 1 month) presenting bleed-
ing manifestations were, as ranked for frequency, central nervous system (CNS),
gastro-intestinal(GI), cephalohaematoma and umbilical bleeding. Several thera-
peutic options are available for patients experience FVII deficiency, which may
result in a very effective correction of the disease [99]. Fresh-frozen plasma is
still used in developing countries, the most important drawback being the blood
volume overload and a relatively high risk of transmitting blood-borne viruses.
Plasma-derived FVII concentrates are essentially prothrombin complex concen-
trates with a higher content of FVII. They are used for prophylactic treatment,
as well as for controlling serious bleeding episodes, and bleeding during surgery.
However, plasma-derived concentrates carry the risk of potential transmission of
blood-borne pathogens. Recombinant FVIIa is to be considered nowadays the
optimal protein replacement therapy. It is free of human plasma and albumin,
so there is no risk of human viral transmission, but it is very expensive and not
available for all patients, particularly in developing countries.
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A considerable number of mutations have been reported to date in FVII gene
(F7 mutation database: http://www.hgmd.cf.ac.uk/ac/index.php). Missense
mutations represent the most frequent portion (fig.1.2) and occur in the 68%
of cases, followed by splicing-site (13%), promoter (8%) and nonsense (6%) mu-
tations, small insertions and deletions (6%) [99, 60, 61]. A number of these
mutations have been identified as the cause of FVII deficiency but only a limited
number of them have been well characterized.
Figure 1.2: Pie chart reporting the percentages of each specific mutation type found in F7
gene.
1.4.1 Background and rationale
In the last years new technologies have been developed in order to control the
expression of human genes by engineering synthetic transcription factors that
can theoretically target any DNA sequence in a specific manner. The capability
of regulating gene expression in the native chromosomal context may represent
a way to address several genetic diseases. This approach also circumvent some
of the traditional challenges of gene replacement, like gene delivery, specific ac-
tivation and immune response related-aspects. Over the past 20 years several
platforms have been developed in order to target a specific DNA sequence and
the most widely used are represented by zinc finger-based transcription factor/nu-
cleases, the transcription activator-like effectors and the CRISPR/Cas9 systems
(figure 1.3). All these systems are based on the exploitation of particular DNA
binding domains (DBDs) that can be associated with several effectors to target a
DNA sequence in order to stimulate a specific biological effect [6]. The first syn-
thetic transcription factors designed to modulate the expression of human genes
were engineered from zinc-finger proteins [114], able to recognize a specific target
through their modular DBD. Despite many achievements in using these modified
zinc finger-based DBDs linked to several actuators in different biological applica-
tion [22, 8, 121, 88], there are many issues related to their engineering that have
limited the widespread adoption of this platform. More recently, another system
protein-based has been developed, starting from a more detailed knowledge of the
structure of the bacterial transcription activator-like effectors (TALEs). Similar
to zinc finger proteins, they show a modular DBD that can be modified in order
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Figure 1.3: Technologies for engineering programmable DNA-binding proteins, including (A)
zinc finger proteins, (B) TALEs and (C) CRISPR/Cas9. Representative crystal structures
of a (A) zinc finger protein or (B) TALE fused to the p65 transcriptional activation domain
or (C) Cas9 (green) bound to a gRNA (blue) and the corresponding DNA target site (brown).
to determine the specificity for a particular sequence in the genome. The possi-
bility in engineering these TALE proteins in a relatively simpler way compared
to zinc fingers has determined their broad usage in the last years [94]. Moreover,
a third technology has emerged based on the RNA- guided DNA endonuclease
Cas9 from the type II bacterial adaptive immune system CRISPR [58]. It differs
from the previous ones because the targeting of a specific DNA loci is due to
the complementary pairing with a guide RNA (gRNA) that form a complex with
Cas9 endonuclease, meaning that the system requires only the exchange of the
nucleotides into the gRNA expression-cassette, and not the design and assembly
of new proteins. Overall, despite the differences in the way of recognizing the
DNA target site, the possibility to deliver a specific actuator to it makes the
spectrum of action of these platform wide, spanning from the gene editing to the
gene activation/suppression [110].
Transcription impairment by mutations in the promoter regions represents a
small, but considerable cause of severe coagulation factor defects and of all inher-
ited human diseases. These mutations often affect only the transcriptional regula-
tory sequences affecting at different extent the expression of completely unaffected
genes. The enhancement of the transcriptional activity could potentially restore
gene expression at therapeutic levels, above all in the case of monogenic diseases.
A recent breakthrough with transcription activator-like effector proteins (TALEs)
makes it possible to establish universal types of engineered TFs (eTFs) that can
potentially target any selected promoter. TALEs are natural effectors found in
the gram-negative Xanthomonas plant pathogen bacteria, secreted into the host
plant cell cytoplasm and then transported into the nucleus where they function
as eukaryotic-like transcription factors. Recognition of specific promoters and
the interaction with the transcriptional machinery lead to the selective expres-
sion of specific host plant genes [102]. TALEs structure consists in a N-terminal
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translocation domain (which permits the protein to be delivered into the cell cy-
toplasm), a C-terminal region composed of a nuclear localization signal (NLS)
and a transcriptional activation domain (AD), and a unique central domain that
determines the DNA binding specificity. Typically, the central region of the pro-
tein contains tandem repeats of 34 amino acids (aa) in length termed monomers
(ranging normally from 7 to 34). Although the sequence of each monomer is
highly conserved, they differ essentially in two positions termed RVDs (repeat
variable di-residues) in position 12 and 13. These two amino acids are respon-
sible for preferential binding of the repeat module to a single specific nucleotide
and a simple cipher specifies the target base of each RVD, where HD, NG/HG
and NI recognize almost exclusively cytosine, thymine and adenine, respectively
[24, 107]. On the contrary, NN has more degenerated specificity (adenine or gua-
nine). Therefore, the linear sequence of the monomers in the protein determines
the DNA target sequence in 5’ to 3’ orientation, such that each repeat contacts
one specific DNA base pair via the RVD. The natural DNA binding site within
plant genomes always start with a thymine, which is contained in a cryptic repeat
of the N-terminal region (NTR) determining the overall basic charge of the TALE
protein [40]. The tandem repeat DBD always ends with an half-repeat, consisting
of 20aa. Hence, the length of the DNA binding site correspond to the number of
full repeat plus two. This simple coding principle has enabled assembly of TALE
repeat arrays for targeting almost any given DNA sequence. The fusion of TALEs
to transcriptional activator, such as the monomer or oligomer of the VP16 acidic
transactivator [21, 12], could generate TALE-TFs that may be used to specifically
induce the expression of a gene as a potential treatment for haplo-insufficiency.
Recently, synthetic TALE- based transcription factors (TALE-TFs) targeted to
the frataxin gene have been used to enhance its expression in Friedreich ataxia
(FRDA) patients fibroblast, down-regulated in presence of a trinucleotide repeat
expansion in the first intron [31]. Moreover, TALE-TFs has been applied in the
development of genetic reprogramming of induced pluripotent stem cells (iPSCs),
thus providing a means for enhancing tissue regeneration and directing cell lineage
specification [27]. However, to our knowledge there are no examples of TALE-TFs
being used to enhance gene expression impaired by promoter mutations leading
to human disease. Interestingly, coagulation factor deficiencies represent a good
target for this type of therapeutic approach, as they would significantly benefit
even from a modest increase in the production of the functional protein.
1.5 Aim of the study
As a model to exploit TALE-TF transcription restoration in coagulation factor
deficiencies, we considered natural promoter mutations impairing F7 gene tran-
scription. It is worth noting that in the F7 mutational pattern a relatively abun-
dant percentage of the cases is represented by the regulatory variants (∼8%), all
reported in the Human Gene Mutation Database (http://www.hgmd.cf.ac.uk/
ac/index.php). In this study we chose two natural promoter mutations found
in patients experience severe FVII deficiency (tab 1.3), the -94C>G and -61T>G
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transversions relative to the initiation codon [18, 29]. The patients homozygous
for these mutations show life-threatening hemorrhagic symptoms and require re-
placement therapy.
Sequence F7 gene Molecular Clinical Number
change region defect severity of cases
-94C>G 5’-flanking region Sp1 binding site Severe 1
-61T>G 5’-flanking region HNF-4 binding site Severe 1
Table 1.3: Synopsis of F7 promoter mutations considered in the study: the relative position
respect the transcription starting site, the transcription factors affected, clinical severity and
number of cases are listed. All the regulatory variants are reported in HGMD-Human Gene
Mutation Database.
The main scope of this project was to explore the ability of engineered TALE-
Transcription Factors (eTFs) to enhance the expression of F7 gene by acting at
the transcriptional level, and to rescue promoter mutations that are associated to
severe FVII deficiency. More specific objectives were the identification of eTFs
able to enhance transcriptional activity on F7 promoter in presence of the muta-
tions impairing gene expression, the assessment of the efficacy and the specificity
of the promoter targeting and the evaluation of their capability in modulating
F7 expression in the endogenous genomic context of human liver and non-liver
cell lines. All these studies were conducted in-vitro to establish the feasibility of
this molecular therapeutic approach, in order to subsequently assess the efficacy
of eTF mediated-rescue of gene expression in specific mouse models.
1.6 Materials and Methods
1.6.1 Design and assembly of TALE-TFs
The 4 customized TALE-TFs targeting the FVII promoter were assembled using
the protocol described by Zhang and colleagues [79] and reagents distributed by
Addgene (Cambridge, MA). TALE-repeat domains were synthesized by hierar-
chical ligation of individual repeat monomers, and cloned into TALE-TF cloning
backbones (available by Addgene). The final TALE-TF expressing-plasmids con-
tain the TALE-derived DNA binding domain, the nuclear localization signal
(NLS), a transcriptional activation domain (VP64), and a 2A sequence followed
by an enhanced EGFP-coding gene.
1.6.2 Construction of the reporter plasmids
– pGL3 FVII wt vector was obtained by amplification of a 520bp human
FVII promoter region from genomic DNA, by using Pfu DNA polymerase
(Thermo Scientific) and with primers containing Hind III recognition site
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at 5’ends: FVII prom F,
5’-AAA AAGCTT CTGTGGCTCACCTAAGAAACCAG-3’
and FVII prom R,
5’-AAA AAGCTTGATG AAATCTCTGCAGTGCTGC-3’
. This region was subsequently cloned into a commercial pGL3 Basic Vector
(Promega) through HindIII sites.
– pGL3 FVII -94G and pGL3 FVII -61G were obtained by site-directed mu-
tagenesis with the primers FVII -94G F
5’-TCCTCCCCTCCGCCATCCCTCTG-3’
and R
5’-CAGAG GGATGGCGGAGGGGAGGA-3’
FVII -61G F
5’-GCAGAGAACGTTGCC CGTCAGTC-3’
and R
5’-GACTGACGGGCAACGTTCTCTGC-3’
respectively. The mutagenesis reaction was performed using QuickChange
II Site-Directed Mutagenesis Kit (Agilent Technologies). All the restriction
reactions were performed with enzymes from NEB (New England Biolabs).
1.6.3 Cell culture and reporter activation assay
The human hepatocyte carcinoma HepG2 and the human embryonic kidney
Hek293 cell lines were maintained under 37◦C, 5% CO2 using Dulbecco’s mod-
ified Eagle’s Medium supplemented with 10% FBS, 2mM GlutaMAX (Invitro-
gen), 100U/ml penicillin and 100 µg/ml streptomycin. Firefly luciferase reporter
activation was assessed by co-transfecting HepG2 cells with plasmids carrying
Luciferase reporters and TALE-TFs. HepG2 cells were seeded into 12-well plates
the day before transfection at densities of 0.2×106 cells/well. Approximately 24h
after initial seeding, cells were transfected using Lipofectamine 2000 (Invitro-
gen). For 12-well plates we used 1 µg of each plasmid TALE-TF and Reporters,
and 100ng of Renilla Luciferase. After about 48h from transfection the reporter
activity was established by luminometer measurement in Dual-Luciferase assay
(Promega). All fold-induction values were normalized to the activity level of Re-
nilla Luciferase for each transfection. All experiments were performed according
to manufacturer’s recommended protocol.
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1.6.4 FACS analysis
HepG2 cells were seeded into a T75 flask 2 days before transfection at density
of 2.1 ×106 cells/flask. Approximately 72h after initial seeding, cells were trans-
fected with 20 µg of the plasmid encoding TF4 using Lipofectamine 2000 (Invit-
rogen). After 24h the transfection efficiency was established by evaluating the
eGFP expression by a fluorescence microscope. After about 48h post-transfection
HepG2 cells were trypsinized, resuspended in a PBS-5 EDTA solution and filtered
through a 50 µm cell strainer to eliminate clumps and debris. eGFP-positive cells
were recovered in DMEM F12 medium after FACS analysis performed with a BD
Facs Aria II sorter (BD Biosciences). The total RNA was extracted with Trizol
Reagent (Invitrogen). The cDNA was generated by iScript cDNA Synthesis Kit
(Bio-Rad) according to the manufacturer’s recommended protocol. F7 transcript
was detected by PCR with primer F7 ex5 F
5’-GAGAACG GCGGCTGTGAG-3’
and F7 ex7 R
5’-GTTCCTCCAGTTCTTGATTTTGTCG-3’
1.6.5 RT-PCR and qPCR for FVII mRNA
HepG2 and Hek293 cells were seeded in 12-well plates the day before transfection
at density of 0.2 ×106 cells/well. After 24h from the seeding cells were trans-
fected with 2 µg of each TALE-TF. Approximately 48h after transfection the
total RNA was extracted with Trizol Reagent (Invitrogen). The cDNA was gen-
erated by iScript cDNA Synthesis Kit (Bio-Rad) according to the manufacturer’s
recommended protocol. F7 transcript was detected by PCR with primer F7 ex5
F and F7 ex7 R. GAPDH, 18S and FVII mRNAs were detected by qPCR using
SsoFast EvaGreen Supermix (Bio-Rad).
1.7 Results
1.7.1 Assembly of engineered TALE-TFs and reporter plas-
mids
The two natural variants we considered, the -94 C>G and the -61 T>G transver-
sions relative to the initiation codon, are reported to falling in the binding site for
the hepato-specific HNF-4 and the ubiquitous Sp1 transcription factors, respec-
tively (Fig. 1.4). The proximal promoter region of FVII gene has been shown to
maintain the maximal promoter activity in HepG2 cells [76], with the HNF-4 and
Sp1 binding sites included in the first 185 bp upstream the translation start site
(TSS). We have therefore generated the reporters vectors for the F7 promoter, wt
and mutants, by cloning 520 bp human F7 promoter region upstream the coding
sequence for firefly luciferase (Fig.1.4), so obtaining the pGL3 FVII wt, pGL3
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Figure 1.4: Scheme representing the reporter plasmids pGL3 FVII wt, -94G and -61G. In
each construct the firefly luciferase expression cassette is cloned downstream the F7 proximal
promoter (520 bp). The reported Sp1 and HNF-4 binding sites with the point mutations are
included in the first 185bp before the TSS.
FVII -94G and pGL3 FVII -61G plasmids. Based on computational analyses of
the F7 promoter and of the transcription factor binding sites in relation with
the position of the nucleotide changes, we performed a tailing design for a panel
of TALE-TFs targeting the functional sequences and resulting in 4 TALE-TF
platforms (TF 1, 2, 3 and 4) covering a region of 70 bp ranging from -122 to
-52 of the F7 5’-flanking region (Fig.1.5). In order to reduce off-target activation
we targeted sequences from 18 to 26 bp in length spanning the region between
Sp1 and HNF-4 binding site on FVII promoter predicted to be unique sites in
the human genome by performing an in–silico analysis. All the constructs are
Figure 1.5: Scheme representing the reporter system. Firefly luciferase gene is regulated by
the proximal promoter region of FVII gene (520bp), wt or mutated, targeted by four different
TALE-TFs (TF1, TF2, TF3 and TF4).
based on a specific TALE-TF cloning backbone which permits the expression of
the customized TALE protein fused with a transcription activator that is, four
VP16 peptides (i.e.VP64), able to recruit the transcriptional machinery on the
target promoter (Fig1.6a). The final TALE-TF expressing-plasmids contain also
a 2A sequence followed by an enhanced EGFP-coding gene (Fig.1.6b).
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Figure 1.6: a) Scheme representing the TALE-TF platform. Each synthetic TALE-TFs is
expressed as a fusion protein composed of a TALE-derived DNA modular binding-domain
and a VP64 transactivation domain, able to recruit the transcriptional machinery on a spe-
cific target promoter to stimulate the transcription of the gene of interest. b) The TALE-TF
expression plasmid is composed of the TALE-derived DNA binding domain, the nuclear local-
ization signal (NLS), a transcriptional activation domain (VP64), and a 2A auto-cleavage
peptide followed by an enhanced EGFP-coding gene. The expression cassette is driven by
the CMV strong promoter.
1.7.2 In vitro models: effect of promoter mutations and
validation of the efficacy of eTFs
The expression of the reporter plasmids pGL3 -94G and pGL3 -61G in HepG2
cell line showed the causative effect of the mutations, with an abolishment of the
firefly luciferase transcriptional levels compared to the pGL3 FVII wt (Fig.1.7).
Most importantly, we observed a robust increase (25±4.9 fold increase for pGL3
-61G and 5.9±0.6 for pGL3 -94G) in the transcriptional levels of the reporter
genes guided by promoter mutants by co-transfecting the cells with TALE-TF 4
(fig.1.7), and thus was confirmed also when it was co-expressed with the pGL3
FVII wt (36.6±17.3 fold increase). Conversely, TALE-TF 1, 2 and 3 did not
show a significant transcriptional activity, either with the mutants and the F7
promoter wt. A negative control was represented by a pBasic vector carrying the
firefly luciferase gene without an upstream promoter sequence (fig.1.7).
1.7.3 Assessment of the specificity of TF4
To investigate more in detail the specificity of TF4, our best candidate, we per-
formed a series of experiments in HepG2 cells by modulating some in-cis and
in-trans elements of the reporter genes transcriptional system. First we co-
transfected TF-4 expressing-vector with the pBasic vector lacking the 5’ promoter
region and, in parallel, with a pSlug vector containing the firefly luciferase guided
by the ubiquitous Slug promoter derived from a Snail gene family of zinc-finger
transcription factors [32]. In both conditions transcriptional levels of the reporter
gene remained unaltered (Figure 1.8). A positive control was represented by the
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Figure 1.7: Co-expression of the reporter plasmids wt, pGL3 -94G or -61G with each synthetic
TALE-TFs in HepG2 cell line. Histograms report luciferase relative activity as change fold
relative to pGL3 FVII wt alone. The negative control is represented by a plasmid pBasic
carrying firefly luciferase gene without an upstream promoter. All the results are expressed
as mean ±SD derived from three independent experiments.
co-transfection of TF-4 with pGL3 FVII wt.
Moreover, to test the DNA binding specificity we introduced 5 mismatches in
Figure 1.8: Co-expression of the TALE-TF4 with pGL3 FVII wt, pBasic or pSlug reporter
plasmids in HepG2 cell line. Histograms of the dual assay report firefly luciferase relative
activity as change fold relative to pGL3 FVII wt alone. All the results are expressed as
mean ±SD derived from three independent experiments.
the TF4 target sequence by site-specific mutagenesis of the plasmids pGL3 FVII
wt and pGL3 FVII -61G, thus creating the pFVII wt ∆T4 and the pFVII -61G
∆T4 vectors. In presence of 5bp changes TF4 DNA binding and transactivation
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capability is virtually abolished, as shown in Figure 1.9. In addition, we tested
Figure 1.9: Effect of TF4 co-transfected in HepG2 with pGL3 FVII wt ∆T4 or pGL3-61 ∆T4
reporter plasmids, expressing firefly luciferase guided by FVII proximal promoter carrying 5
mismatches in TALE-TF4 binding site. The negative control is represented by pBasic vector.
All the results are expressed as mean ±SD derived from three independent experiments
the TALE-DNA binding domain-play role by co-transfecting pGL3 FVII wt, -61G
and -94G variants with a pHD plasmid expressing the VP64 transactivator with-
out the TALE-derived DBD, and even in this case any substantial enhancement
in firefly relative activity was appreciable (Figure 1.10).
Figure 1.10: Co-transfection of HepG2 cells with the pGL3 FVII wt, -61G or -94G with a pHD
backbone vector expressing the VP64 transactivation domain alone. Histograms of the dual
assay report firefly luciferase relative activity as change fold relative to pGL3 FVII wt alone.
All the results are expressed as mean ±SD derived from three independent experiments.
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1.7.4 Effect of TF4 in the endogenous context of HepG2
cells
To assess the capability of TF4 in enhancing gene expression in the genomic
context we targeted the endogenous F7 promoter in HepG2 cells. Because of
the low transfection efficiency assessed in this cell line by using lipofectamine
method (<10%), we took advantage of the eGFP expression from the TF4 coding-
vector (fig.1.6b) thus selecting eGFP positive-HepG2 post-transfection by FACS
analysis. Total RNA was then extracted from both eGFP-positive and negative
cells, followed by a specific RT-PCR in order to detect F7 mRNA. In the eGFP-
positive HepG2 (+TF4) the F7 transcript amount was increased compared to
eGFP-negative cells (fig.1.11a). The quantification of F7 mRNA levels through
qPCR showed an increase by 2.3±0.2 fold (P <0.01) after treatment with TF4
(fig.1.11b). Data analyses were performed with T-Student test comparing TF4-
treated cells with untrasfected mock cells; * p < 0.05; ** p < 0.01.
Figure 1.11: Effect of TF4 on the FVII transcriptional levels in HepG2 endogenous context.
a) RT-PCR performed on cDNA from HepG2 eGFP positive and negative (mock) cells. F7
transcript was amplified using a primer F on exon 5 (Ex5) and a primer R on exon 7 (Ex7).
PCR products (312bp) were detected by gel electrophoresis on agarose gel 2%. b) Levels of
FVII mRNA in transfected GFP positive-HepG2 cell compared to the mock, as determined
by relative qPCR. All the results are expressed as mean ±SD derived from three independent
experiments. The change folds are reported to 18S housekeeping gene expression.
1.7.5 Effect of TF4 in the endogenous context of Hek293
cells
We tested TF4 transcriptional activity also in the endogenous context of Hek293
cells that normally do not express F7 gene (http://webserver.mbi.ufl.edu/
~shaw/293.html), as confirmed from our experimental data. Hek293 cells were
treated with TF4, and the presence of F7 mRNA was confirmed by specific RT-
PCR. Conversely, in the mock non-treated Hek293 cells no F7 mRNA was de-
tectable, as expected (fig.1.12a). The increase in F7 mRNA levels was quantified
18 1. TALE TFs
by qPCR and established at 6.3±1.3 fold (P <0.05) compared to the mock cells
(fig.1.12b). Data analyses were performed with T-Student test comparing TF4-
treated cells with untrasfected mock cells; * P < 0.05.
Figure 1.12: Effect of TF4 on the FVII transcriptional levels in HeK293 endogenous context.
a) RT-PCR performed on cDNA from Hek293 TF4-treated and non-treated cells. F7 tran-
script was amplified using a primer F on exon 5 (Ex5) and a primer R on exon 7 (Ex7).
PCR products (312bp) were detected by gel electrophoresis on agarose gel 2%. b) Levels of
FVII mRNA in TF4-treated Hek293 cells compared to the mock (transfected with the lipo-
fectamine vehicle), as determined by relative qPCR. All the results are expressed as mean
±SD derived from three independent experiments. The change folds are reported to 18S
housekeeping gene expression.
1.7.6 Effect of the TF1, TF2 and TF3 in the endogenous
context of HepG2 and Hek293 cells
As experimental control HepG2 and Hek293 cells were transfected with TF1, 2
or 3, even if they did not show appreciable transcriptional activity in the gene
reporter assays (fig1.7). F7 mRNA levels were quantified by qPCR and nor-
malized to the untreated cells. The F7 mRNA was increased by 1-1.5 fold (P
value=ns) in HepG2 cells (fig.1.13a) and by 2-3 fold in Hek293 cells (fig.1.13b),
a non-significant effect compared to TF4 treatment (fig.1.12a). Data analyses
were performed with one-way ANOVA and Bonferroni correction for multiple
comparisons (TFs compared to the mock).
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Figure 1.13: Effect of TF1, TF2 and TF3 on the FVII transcriptional levels in HepG2 and
HeK293 endogenous context. a) Levels of FVII mRNA in HepG2 cells treated with TF1,
2 and 3 compared to the mock untreated cells, as determined by relative qPCR. All change
folds are reported to 18S housekeeping gene expression. b) Levels of FVII mRNA in Hek293
cells treated with TF1, 2 and 3 compared to the mock untreated cells, as determined by
relative qPCR. All the results are expressed as mean ±SD derived from three independent
experiments. All change folds are reported to 18S housekeeping gene expression.
1.7.7 Discussion and future perspectives
The in-vitro study is part of a wider project focused on the genetically-determined
deficiencies of blood coagulation factors that, in the most severe cases, are asso-
ciated to life-threatening bleeding symptoms, sometimes also fatal. It is worth
noting that in these pathologies even modest increase of functional protein lev-
els in plasma significantly ameliorates the bleeding phenotype. FVII deficiency
due to promoter mutations represents a good model to investigate the ability of
engineered TFs of enhancing gene transcription for therapeutic purposes. As a
matter of fact, increased expression of F7 gene may reduce or completely reverse
the symptoms of this deficiency, given that patients have been shown to receive
benefit from restored level of proteins up to 6% [98]. In this in-vitro study the
model of FVII deficiency has been validated for the promoter variants -94C>G
and -61T>G by exploiting gene reporter assays in HepG2 cell line, due to the im-
possibility of conducting the experiments in primary hepatocytes from patients,
which are not available. These mutations, by altering the DNA binding sites for
the natural transcription factors Sp1 and HNF-4 [18, 29], lead to a consequent
decrease in the functionality of the promoter and reduce the transcriptional levels,
as confirmed by the firefly luciferase reporter assays (fig.1.7). The screening with
four engineered TFs designed to recognize different target sequences spanning
from Sp1 to HNF-4 binding sites on F7 promoter allowed the identification of
TF4, that showed a robust enhancement of the transcriptional activity (from ∼6
to 50 fold increase, depending on the variant considered, fig.1.7). The different
changes in the expression levels for the mutants -94C>G and -61T>G (fig.1.7)
could be explained by a different DNA-protein interaction framework governing
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transcription in the different mutant context. Besides, it is important to note
that the increased expression is observable also in the presence of the F7 pro-
moter wt, while the treatment with the TF1, 2 and 3 is no effective in any case
(fig.1.7), thus giving important information on the promoter accessibility. The
reason why only TF4 is effective could be at least in part attributable to the
position of its target sequence between the Sp1 and HNF-4 binding sites. This
probably represents the best positioning from the TSS in close proximity to the
endogenous TFs binding sites in order to recruit the transcriptional machinery,
and to avoid the competition of the TF4 with the other TFs on their own DNA
binding sites. An important issue that has to be considered in the correction
approach with engineered TFs is the specificity, since there is a potential risk
arising from non-specific DNA-TF interactions that would lead to the alteration
of off-target gene expression. One way to improve the specificity is a careful
design of the protein DBD. For this purpose the four TFs were assembled to
recognize DNA sequences from 18 to 26bp in length that, by in-silico analyses,
are predicted to be unique into the genome. We focused in particular on the
potential off-target effects that could be induced by the treatment with TF4,
the only effective, testing its binding specificity by modulating some elements in
the fusion protein itself and in the target sequence. The co-transfection of TF4
expressing-plasmid with the pSlug vector carrying firefly luciferase under the
control of the Slug promoter showed no increase in the reporter activity (fig.1.8),
thus supporting the specificity for F7 promoter. Most importantly, we found that
5 mismatches in the TF4 target sequence (fig.1.9) are able to abolish the TF4
transactivation capability, thus strengthening a mechanism strictly dependent on
the highly specific target sequence, as previously reported [41]. We confirmed
that the recruitment of the transcriptional machinery by eTF4 on the promoter
is specifically due to its binding with the DNA by testing the activity of VP64
lacking the TALE-derived DBD. The co-expression of VP64 alone in presence of
the F7 promoter wt, as well as the two mutants, did not showed any change in
the reporter relative activity (fig.1.10). Data obtained from the gene reporter
assays showed the efficacy of TF4 that is able to efficiently recruit the transcrip-
tional machinery and rescue the expression of the reporter otherwise abolished in
presence of the disease-causing mutations. However, it is worth noting that the
reporter genes episomal system may not be representative of the physiological
context, because it does not permit to take into account the chromatin context.
To address this issue we assessed the activity of the four eTFs on the endogenous
F7 gene expression in HepG2 and Hek293, which express or not express FVII,
respectively. In HepG2, a human hepatoma cell line, the treatment with TF1,
2 and 3 had a minor impact on F7 mRNA levels, with the maximum change
fold measured around 1.5 (fig.1.13a), reflecting the previous data obtained with
the gene reporter system. On the other hand, the treatment with eTF4 showed
a more robust increase in F7 mRNA levels (fig.1.11a) established to be 2.3±0.2
fold. Surprisingly, this fold increase was markedly less pronounced as compared
to that observed in the episomal plasmid context with the F7 promoter wt vec-
tor (fig.1.7). It is therefore possible to argue that chromatin environment has a
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strong impact on the capability of the eTF to bind efficiently F7 promoter and/or
to enhance transcription via VP64. This finding is supported by other literature
data in which the magnitude of gene activation by eTFs at native chromosomal
loci was relatively modest [66, 93].
Nevertheless, it has also to be considered that the enhancement achieved is
referred to its action on the F7 promoter wt, thus supporting the idea that a
major improvement could be reachable in presence of promoter mutations. Ex-
periments conducted in human embryonic kidney Hek293 background showed F7
mRNA levels increased from 2.2±0.3 (+TF3, fig.1.13b) to 6.3±1.3 times (+TF4,
fig.1.12b). It is worth noting that Hek293 cells normally do not express FVII (as
revealed by RT-PCR and qPCR experiments in the transfected cells), though af-
ter treatment with TF4 F7 mRNA was clearly detectable by RT-PCR (fig.1.12a).
This data confirms the capability of TF4 in actively stimulating F7 gene ex-
pression in Hek293 cells. The different behavior in HepG2 and Hek293, with
a surprising activity in Hek293 cells in which the transcription on F7 promoter
is normally down-regulated, may underlie a competition of TF4 with the liver
specific HNF-4 in HepG2 (http://www.cisreg.ca/cgi-bin/tfe/articles.pl?
tfid=140&tab=expression).
Overall, these results suggest that TF4 should be able to increase expression of
the F7 gene in patient cells. This may potentially reduce or completely reverse the
symptoms of FVII deficiency, as patients with FVII deficiency have been shown
to receive benefit from restored levels of protein up to 6% [98]. We are conscious
that the study in vitro, by exploiting reporter gene assay, does not permit the
evaluation of eTFs effect on the proper chromosomal context and thereby the ef-
ficacy of TF4 has to be validated in a proper model of FVII deficiency caused by
promoter mutations. Future experiments will be addressed to test the detrimental
impact of human F7 promoter mutations in the murine environment by trans-
fecting expression vectors, either wt or mutated, in Hepa1-6 murine cells. Normal
or impaired expression of the human FVII gene will be evaluated by qRT-PCR.
Mutations that will affect transcription to similar extent in the human and mouse
liver cell lines will provide the rationale for the subsequent experiments in-vivo.
These will be conducted in specific mouse models for promoter mutations created
by zygote injection of plasmids encoding CRISPR-Cas9 system to target the F7
murine promoter or a safe locus and insert the human F7 (hF7) gene under the
control of the human promoter, either wild-type (positive control) or bearing the
natural mutations. In our hypothesis, the mutations would prevent the apprecia-
ble expression of the hFVII in mouse liver, and thus the presence of circulating
protein. Injection of liver-specific AAV vectors expressing TF4 in these new an-
imal models and evaluation of hFVII expression at the mRNA and protein level
will permit the assessment of the correction efficacy in vivo. Moreover, a proper
animal model will permit the determination of the optimal delivery method, the
characterization of the specificity in the gene regulation and the evaluation of the
immunogenicity of the synthetic proteins, very important issues when proposing
an innovative therapy.
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Chapter 2
SB Transposon
2.1 Focus on FIX: gene and protein features
2.1.1 Factor FIX protein
Human coagulation factor IX, also called Christmas factor or antiemophilic B
factor, is a single chain glycoprotein synthesized in liver and circulating in blood
like a zymogen at a physiologic concentration of 5 µg/ml [1]. As FVII it features
a N–terminal γ–carboxyglutamic acid–rich domain followed by two EGF–like do-
mains and the C–terminal serine protease domain. The mature protein consists of
415 aminoacids of 57 KDa molecular weight. The first 40 aminoacids constitute
the γ–carboxyglutamic (Gla) domain, which contains post-translational modifica-
tions of many glutamate residues by vitamin K–dependent carboxylation to form
γ–carboxyglutamate (Gla). The Gla residues are responsible for the high-affinity
binding of calcium ions [101, 117, 54], so conferring to FIX its biological activ-
ity. Then the protein consists of a short hydrophobic segment (residues 41-46),
two EGF–like domains (residues 47-84 (EGF1) and 85-127 (EGF2)), an activa-
tion peptide region (residues 146-180), and a serine protease module (residues
181-415). Activation of FIX involves proteolytic cleavages at Arg145-Ala146 and
Arg180 and Val181 bonds with a concomitant release of a 35-residue activation
peptide (3, 40). The FIXa thus formed contains a light chain (residues 1-145) and
a heavy chain (residues 181-415) held together by a single disulfide bond. The
light chain consists of the Gla, EGF1, and EGF2 domains whereas the heavy
chain contains the serine protease domain that features the catalytic triad of
residues His-c57221, Asp-c102 269 and Ser-c195 365 [118, 103, 2].
2.1.2 Factor FIX gene
The gene of human factor IX (F9) is localized in q27.1-q27.2 region of chromosome
X. Isolated and sequenced in 1985 [91] it is approximately 34kb in lenght and
contains eight exons (spanning from 25bp to 548bp) and seven introns. The
transcript is 2803 bases in length and comprises a short 5‘ UTR (29 bp), an open
reading frame (1383 bp) and a 3‘ UTR (1390 bp). Exon 1 and part of exon
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Table 2.1: Factor IX gene exons organization
2 encode for the pre-pro leader sequence, which is removed during the protein
biosynthesis, while the last part of exon 2 together with exon 3 encode for the
Gla domain containing 12 γ–carboxiglutamic acid residues. The γ–carboxilation
is a modification needed for the proper folding of the FIX and for its calcium
binding capacity. Exons 4 and 5 encode respectively for the first and the second
epidermal growth factor-like domains (EGF-like 1 and 2). Exon 6 codes for the
activation domain, in which factor IXa and the complex FVIIa-TF cut in order to
activate FIX. The last two exons encode for the catalytic domain of the protein
(tab.2.1) [17].
2.2 FIX deficiency-Haemophilia B
Haemophilia B, or Christmas disease, is an inherited, X-linked, recessive disor-
der that results in deficiency of functional plasma coagulation factor IX [11]. It
has a prevalence of around 1 in 30,000 live births (about five times rarer than
haemophilia A). There are usually carrier females and affected males. The clas-
sification of the severity of haemophilia B is based on either clinical bleeding
symptoms or plasma pro-coagulant levels; the latter are the most widely used
criteria.
• Severe disease occurs with a factor IX level below 1% of the reference and
accounts for about 50% of cases.
• Moderate severity occurs with a level of 1-5% and accounts for around 30%
of cases.
• Mild disease is with levels of 6-30% and accounts for around 20% of cases.
People with mild haemophilia B typically experience bleeding only after serious
injury, trauma or surgery and in many cases the disease is not diagnosed until
an injury, surgery or tooth extraction results in prolonged bleeding. Women with
2.3 Background and rationale 25
mild haemophilia often experience menorrhagia, heavy menstrual periods and can
hemorrhage after childbirth. People with moderate haemophilia tend to bleed af-
ter injuries, and finally people with a severe phenotype may have also frequent
spontaneous bleeding episodes, often into their joints and muscles. The current
treatment is based on the intravenous administration of FIX (replacement ther-
apy), either plasma derived or recombinant [106, 119]. Since even small increase
in FIX levels (>2%) would result in significant amelioration of the clinical pheno-
type, HB represents a model to investigate innovative therapeutic approaches in a
quantitative manner, by virtue of functional and protein assays in plasma. Enor-
mous efforts have been pushed on substitutive gene therapy, and very recently it
has been demonstrated that intravenous infusion of a AAV vector encoding FIX
in HB patients resulted in FIX expression ranging from 1% to 6% for periods of 2
years, with amelioration of bleeding phenotypes [104, 68]. DNA editing by using
zinc finger nucleases has been also exploited in HB mouse models [53]. However,
there are still limitations regarding the delivery method to the target site and
safety of gene therapy that encourage research towards alternative therapeutic
approaches.
Figure 2.1: Pie chart showing the F9 mutational pattern reported in the Haemophilia B
Mutation Database.
2.3 Background and rationale
In the last years enormous efforts have been made to develop therapeutic ap-
proaches for human genetic diseases alternative to protein replacement therapy.
The most remarkable results arise from the gene therapy field that has shown
its huge potential in the cure of diseases such as primary immunodeficiencies
[15, 14, 44], Leber’s congenital amaurosis [57], cancer [9], Fanconi’s anemia [85]
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and, recently, Haemophilia B [68, 69]. The concept behind gene replacement is
very simple, concerning the possibility of efficiently transferring and expressing
a normal copy of a defective gene into target cells [115]. Fascinatingly, the ad-
vances in biotechnology have allowed the therapeutic technique to move from
the conceptual stage to its application in patients for clinical trials for a variety
of disorders. To date, from 1989 to 2014 over one thousand gene therapy clin-
ical trials have been completed, are ongoing or have been approved worldwide
(http://www.abedia.com/wiley). However, there are still issues that limit the
wide applicability of these approaches. Limitations are related to the transgene
size, the long-term expression and the regulation of the therapeutic gene, to
the immune response, to the nature of the DNA vehicle and to harmful effects
such as insertional mutagenesis when the transgene is integrated into the genome
[5]. Therefore, research is still pushed towards alternative and/or complementary
therapeutic strategies based on the correction of the specific disease-causing de-
fects, in order to try to circumvent some of these limitations. These approaches
are of great interest especially for patients that would benefit even by small
increase in functional protein levels, as it happens in the case of coagulation dis-
orders (http://www.haemophilia.org). HB is a prototypical example of disease
with a heterogeneous mutational pattern (www.factorix.org) and a relatively
high frequency of splicing mutations (>15%) in severe disease forms. Mutations
inducing aberrant splicing, at splice junctions or within exons, can be addressed
by intervention at the pre-mRNA level and this therapeutic approach have been
intensively studied by us to correct splicing mutations causing severe HB and
FVII deficiency [37, 74, 75, 19]. In particular, we proposed the development of
modified U1 small nuclear RNA (U1 snRNA), fundamental component of the
U1small nuclear ribonuclearparticle (U1snRNP) with an essential role in exon
definition [108], to restore exon inclusion during pre-mRNA maturation impaired
by exon-skipping causing mutations.
2.4 Exon Specific U1s (ExSpeU1s) as therapeu-
tic tool
An early event in exon definition is the recognition of the 5’ss by the U1 snRNP,
which is composed by a 164bp-long U1 snRNA associated to U1-specific proteins
(U1-70K, U1A and U1C) and Sm proteins that are also present in the other
snRNPs [108]. The gene coding for the U1 RNA is present in multiple copies
in the human genome, is highly evolutionary conserved and possesses its own
specific Pol II promoter and polyA site in a short gene long ∼ 600bp . The as-
sembly of the spliceosome in the early phase of the splicing process begins with
the recognition of the 5’ splice site (5’ss) sequence by the U1snRNP through its 5’
RNA tail [78, 89], which U1 snRNP-associated proteins U1-70K and U1 stabilize
this transient interaction. Another important step following the U1 snRNP-5’ss
binding is the recognition of the 3’ss mediated by the U2 auxiliary factor [81].
The subsequent establishment of multiple interactions between the 3’ss and the
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5’ss defines an exon, and constitutes the commitment step towards the splicing
pathway [116, 4]. U1snRNP, through its U1A component, is also involved in the
polyadenilation of the pre-mRNA and modified U1snRNAs with a tail that hy-
bridize to the 3’-UTR of target transcripts have been tested for modulating gene
expression [23, 52, 51]. The 5’-tails of U1 snRNAs has been previously altered
in order to deliver antisense sequences. A modified U1snRNA targeting mouse
DMD gene exon 23 3’ss and 5’ss was systemically delivered using AAV vectors
to the dystrophin-deficient mouse model of DMD, and Body-wide dystrophin
restoration was observed in treated mice. [34]. More recently, investigators used
U1 snRNAs to correct splicing through exon skipping in human DMD pre-mRNA
in primary patients fibroblasts [30]. A limited number of studies have explored
the role and potential therapeutic effects of U1 snRNAs in correcting donor splice
site mutations in cellular models [74, 20, 43, 73, 80, 83, 84]. Recently, the first
“proof of concept” that a modified U1 snRNA is able to rescue mRNA processing
and protein biosynthesis of coagulation factor VII (FVII) has been provided in
mouse models expressing the splicing defective 5’ss human FVII transgene [19].
In all cases, the modified tails of the U1snRNAs have few nucleotide changes in
comparison to the wt sequence and base pair to the mutant donor sites. However,
this approach has limitations that reduce its potential applicability in therapy.
First of all, it implies the use of a specific modified U1 snRNA for each pathogenic
mutation, hardly conceivable for the development of therapies for the majority of
human genetic disorders in which the mutational pattern is highly heterogeneous
with several different splicing mutations. Moreover, modified U1 snRNAs comple-
mentary to the 5’ss might target by complementarity similar donor splicing sites
and thus potentially interfere with splicing of other pre-mRNAs with toxic ef-
fects. As a matter of fact, in our in-vivo studies we observed liver toxicity in mice
injected with the highest doses of adeno-associated viral vector (AAV) expressing
the modified U1 RNAs[19], which might point toward off-target effects. The use
of Exon Specific U1snRNAs (ExSpeU1s) recently identified in our group [37] rep-
resents a novel promising strategy to overcome the above mentioned limitations.
ExSpeU1s are designed to bind by complementarity to intronic sequences down-
stream of the exon donor splice site and rescue different types of splicing defects
associated to exon skipping, a very common pathogenic mechanism. Binding of
the ExSpeU1s to non-conserved intronic sequences could significantly reduce the
possibility of off-target events. ExSpeU1s are active on several 5’ss mutations, on
mutations in the polypyrimidine tract and on defective splicing caused by exonic
variants [37]. Most importantly, we demonstrated that a unique ExSpeU1 is able
to correct several mutations inducing exon skipping of a given exon, thus provid-
ing a potential therapeutic tool for a cohort of patients and not only for very few
of them. We exploited ExSpeU1s in cellular models of coagulation factor IX (FIX)
deficiency, Cystic Fibrosis and Spinal Muscular Atrophy and demonstrated that
they are able to rescue gene expression to a significant extent [37]. The ExSpeU1
therapeutic approach acting at pre-mRNA level has the advantages of maintain-
ing the transcriptional gene regulation and of guaranteeing the correction in the
physiologic tissues only. Moreover, it is based on the use of small sequences that
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can be packaged virtually in any viral vector so far successfully tested for re-
placement gene therapy purposes. This previous data encouraged studies aimed
at further improving this approach and at testing it in animal models.
2.5 Creation of a stable model: the Sleeping
Beauty transposon system (SBTS)
The creation of proper cellular and mouse models of HB caused by splicing muta-
tion was performed by exploiting the Sleeping Beauty transposon system (SBTS),
one of the promising technology platform for gene transfer in vertebrates [115].
SB is a synthetic transposable element that has been generated by reverse engi-
neering from defective copies of an ancestral Tc1/mariner-like active vertebrate
element from ”dead” transposon fossils found in salmonid fish genomes, which
was so named Sleeping Beauty [48]. In its natural form, SB transposon consists of
a single gene encoding the transposase enzymatic factor of transposition, which
is flanked by terminal inverted repeats (ITRs) containing binding sites for the
transposase itself (fig 2.2) [113]. Specific binding to the ITRs is mediated by
an N-terminal, paired-like DNA binding domain of the transposase [48, 47, 49]
that overlaps with a nuclear localization signal (NLS) [47]. An AT-hook motif
has also been identified as a functional subdomain that is involved in the DNA
binding [49]. The catalytic domain of the transposase mediates the DNA cut-
ting and the subsequent integration reactions and is characterized by the DDE
signature, an evolutionary conserved domain also found in some bacterial trans-
posases, retrotransposon/retrovirus integrases and the RAG1 immunoglobulin
gene recombinase [35]. The transposase gene can be physically separated from
Figure 2.2: The Sleeping Beauty transposable element and the transposition mechanism. (A)
Components of the element. On top, a schematic drawing of the transposon is shown. The
element has a single gene encoding the transposase, which is flanked by terminal inverted
repeats (IR/DRs, blue arrows), each containing two binding sites for the transposase (small
green arrows). The transposase has an N-terminal, bipartite, paired-like DNA-binding do-
main containing a GRRR AT-hook motif, a nuclear localization signal (NLS), and the DDE
catalytic domain.
the ITRs and replaced by other DNA sequences, because transposase enzyme can
mobilize transposons in trans, as long as they retain the ITRs. The transposase
gene can be located on the same DNA molecule as the transposon [64], or supplied
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by another DNA molecule [124], or supplied in the form of either mRNA [36] or
protein. The SB technology used in this study is based on a two-vector system
(fig. 2.3). The transgene of interest is cloned into the transposon plasmid within
Figure 2.3: SBTS two-vectors platform. A)The transgene of interest is cloned into the trans-
poson plasmid within the inverted terminal repeats (ITRs), which are recognized by the hyper-
active transposase SB100X, encoded by a plasmid provided in trans. B)SB100X hyperactive
transposase binds to the ITRs and cuts the transposon out of the plasmid. The transgene
can subsequently be integrated in a new site into the recipient DNA.
the ITRs recognized by the transposase SB100X, encoded by a plasmid provided
in trans (fig.2.3A). The SB100X is an hyperactive transposase recently derived
from a large-scale genetic screen in mammalian cells, with∼100-fold enhancement
in efficiency when compared to the first-generation transposase [48, 67]. SB100X-
mediated transposition is a cut-and-paste mechanism (fig.2.3B), during which the
transposable element located within the ITRs is excised from its original location
and the two ends of the elements are paired and held together by transposase
molecules to form a synaptic complex [123]. Finally the transposable element is
reintegrate at a target site, which for SB100X is preferentially a TA dinucleotide
that is duplicated upon transposition and flanks the integrated element [49, 124].
The gene transfer mediated by SB100X transposase has been proven to be highly
efficient in cellular and mouse models, and to permit the long–lasting expression
of human coagulation factor FIX (hFIX) in–vivo [62].
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2.6 Aim of the study
The aim of this project was to exploit the Sleeping Beauty transposon system
for the development of cellular and mouse models of HB caused by F9 splicing
mutations, and then to assess the efficacy of the ExSpeU1s-mediated correction
approach in the chromatin expression context instead of a transient episomal sys-
tem. Indeed, in contrast to other approaches, the SBTS non-viral system enables
the transgene to be integrated into the genome, which represents the preferred
physiologic situation for subsequent splicing studies. As a model, we chose the
splicing mutation FIXex5-2C, a single point change falling in the exon 5 donor
splice site and causing exon skipping [37]. Data obtained by exploiting minigene
assays revealed that this variant can be rescued by a modified U1snRNA de-
signed to have full complementarity to the mutant 5’ss named U1FIX-2C (fig.2.4
B), as well as by some modified U1 snRNA complementary to downstream in-
tronic sequences, named exon-specific U1 (ExSpeU1) and able to redirect the
spliceosome machinery on the mutated donor splice site in order to restore the
exon 5 definition. Here we consider the ExSpeU1 sh9, one of the most effec-
tive in rescuing the FIXex5-2C variant and base pairing at 9 bp downstream of
the 5’ss of F9 exon 5 (fig.2.4C). The usage of the ExSpeU1, like U1sh9, permits
Figure 2.4: Schematic representation of binding sites of the U1 wt, U1FIX-2C and U1sh9 in
F9 exon 5 context. Donor site and downstream intronic region are shown and exonic and
intronic sequences are in upper and lower case, respectively. A) Binding of the U1 wt on the
exon 5 donor splice site in presence of the FIXex5-2C variant, marked in red. B) Binding of
the modified U1 FIX-2C, designed to perfectly match the exon 5 mutated 5’ss. C) Binding
of the ExSpeU1 sh9, designed to base pair at 9 bp downstream of the 5’ss of F9 exon 5.
to target non-conserved intronic sequences downstream of the 5’ss, in order to
improve specificity and reduce potential off-target effects on other pre-mRNAs.
Moreover, it permits the exploitation of a unique ExSpeU1 to correct a panel of
different exon-skipping mutations, thus extending its applicability to a cohort of
patients sharing the same pathogenic mechanism (i.e. skipping of a given exon)
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[37]. However, the efficacy of the ExSpeU1s have been demonstrated in cellular
models only and in an episomal expression system using plasmids, and not in
experimental system in which the splicing defective transgene in integrated into
the genome. The final goal of our pioneer approach with the SB is to integrate
the wt or mutated human splicing-competent FIX cassettes (SC-FIX) into the
genome of human and mouse hepatocytes to induce the stable expression of the
FIX pre-mRNA, in order to validate the efficacy of the ExSpeU1 sh9 in both the
in–vitro and emphin–vivo models.
2.7 Materials and Methods
IN-VITRO STUDY
2.7.1 Vectors and cloning of the transposon plasmids
All the vectors used for the creation of the cellular models are composed of the
expression cassettes cloned into a commercial pT2-SVNeo plasmid (available from
Addgene) containing the ITR sequences recognized by the transposase SB100X.
The transposase enzyme is codified by a commercial plasmid, pCMV(CAT)T7-
SB100 (abbreviated pSB100X, available from Addgene).
• pT2 SChFIX wt and pT2 SChFIX -2C were obtained by PCR amplification
of the splicing-competent hFIX cassette from the plasmid pBSK-FIX IVS
4-5 and pBSK-FIX IVS5-2C [37], by using Pfu DNA polymerase (Thermo
Scientific) and with primers containing XmaI recognition site at 5’ends: F9
XmaI F,
5’-AAACCCGGGACCACTTTCACAATCTGCTAGC-3’
and F9 XmaI R
5’-AAACCC GGGTCCTAACACATTATATTCCTCTAGTGG-3’
The amplification products were subsequently cloned into a commercial
pT2-SVNeo (Promega) through XmaI sites.
• pT2-eGFP plasmid was obtained by PCR amplification of the eGFP coding-
sequence from a previous pPKCβ–eGFP plasmid, by using Pfu DNA poly-
merase (Thermo Scientific) and with primers containing XmaI recognition
site at 5’ends: EGFP F,
5’-AAA CCCGGGATGGTGAGCAAGGGCGAGGAG-3’
and EGFP R
5’-AAACCCGGGTTACTT GTACAGCTCGTCCATGC-3’
This region was subsequently cloned into a commercial pT2-SVNeo (Promega)
through XmaI sites.
32 2. SB Transposon
2.7.2 Cell culture and generation of Hek293 stable clones
The human embryonic kidney Hek293 cell lines were maintained under 37◦C, 5%
CO2 using Dulbecco’s modified Eagle’s Medium supplemented with 10% FBS,
2mM GlutaMAX (Invitrogen), 100U/ml penicillin and 100 µg/ml streptomycin.
Hek293 cells were seeded into T75 flasks 3-4 day before transfection at densities of
2 ×106 cells/flask. For the generation of Hek293 stable clones cells have been co-
transfected using Lipofectamine 2000 (Invitrogen) with pT2-splicing competent
hFIX variants and pT2-eGFP at a molar ratio of 5:1, in combination with the
transposase expressing-plasmid pCMV(CAT)T7-SB100 in ratio 1/20 of the total
DNA (25 µg). Ten days post-transfection, the GFP-positive cells have been
isolated by FACS analysis through a BD Facs Aria II sorter (BD Biosciences)
and expanded in a T25 flask. Polyclonal cells from the selection step were then
plated at a density of 10cells/ml on 148cm2 petri dishes for stable clones isolation.
When the size of the cell colonies formed on the petri dish reached about 2-3 mm
in diameter (about two weeks after plating), a number of eGFP expressing clones
were picked for each construct by using cloning cylinders in which 0.2 ml of the
5% trypsin-PBS solution was added. Single colonies were transferred to a 24-well
and expanded for subsequent analyses.
2.7.3 Evaluation of the hFIX stable expression
The hFIX expression in Hek293 eGFP positive clones has been evaluated at the
RNA and secreted protein level. The total RNA was extracted from cells at
confluency in a 6-well plate (around 1.2 ×106 cells) with Trizol Reagent (In-
vitrogen) and treated with DNase (Ambion-Life Technologies). The cDNA was
generated by RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific) ac-
cording to the manufacturer’s recommended protocol. F9 transcript was detected
by PCR with primer hFIX Ex4F (5’-ATTCCTATGAATGTTGGTGTCCCT-3’)
and hFIX Ex6R (5’-GGGTGCTTTGAGTGATG TTATCCAA-3’). The condi-
tions used for the PCR were 94◦C for 5 min for the initial denaturation, 94◦C
for 30s, 56◦C for 30s, 72◦C for 30s for 30 cycles and 72◦C for 10 min for the final
extension. The evaluation of the protein levels was performed by a Factor IX
Antigen Kit (Affinity Biologicals) on the culture medium samples according to
the manufacturer’s recommended protocol.
2.7.4 Evaluation of the gene copy number in Hek293 sta-
ble clones by Southern blot
The copy number of the hFIX transgene in Hek293 stable clones was exam-
ined by Southern blot analysis. Briefly, genomic DNA was extracted from the
cells by Gentra Puregene Cell Kit (Qiagen), and digested over night by re-
striction enzyme XbaI. After electrophoresis on agarose gel 0.7% at 35V 4-5
h the digested DNA was transferred to a Nylon membrane through iBlot Dry
blotting System (Invitrogen). The membrane was subsequently denatured in
a 1.5M NaCl/0.5M NaOH solution and maintained in a hybridation buffer to
2.7 Materials and Methods 33
block non-specific sites. The probe was made by amplification of a 390 bp
sequence of the hFIX transgene with AccuPrime Taq polymerase (Life Tech-
nologies) and with primer (Probe F (5’-TGCAGCGCGTGAACATGATC-3’) and
R (5’-CTAATTCACAGTTCTTTCCTTCAA-3’). The denatured DNA product
was labeled with alkaline phosphatase trough Amersham AlkPhos Direct La-
beling and Detection Systems (GE Healthcare) according to the manufacturer’s
instructions. The hybridization with the membrane was carried out overnight at
37◦C. The day after membrane was washed and hybridized blots were detected
by adding ECF substrate and by scanning at Storm Imager 840 (Molecular Dy-
namics) in chemifluorescence mode, 100microns, 650V.
2.7.5 Transfection with U1snRNA sh9
Hek293 cellular clones were seeded into 6-well plates the day before transfection at
densities of 0.3 ×106 cells/well. After 24h from the seeding cells were transfected
with 2µg of the plasmid expressing modified U1sh9. Approximately 48h after
transfection the total RNA was extracted with Trizol Reagent (Invitrogen) and
treated with DNase (Ambion-Life Technologies). The cDNA was generated by
RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific) according to
the manufacturer’s recommended protocol. F9 transcript was detected by PCR
with primer hFIX Ex4F and hFIX Ex6R. The evaluation of the protein levels
was performed by a Factor IX Antigen Kit (Affinity Biologicals) on the culture
medium samples according to the manufacturer’s recommended protocol.
2.7.6 AAV-expressing U1sh9
The recombinant AAV8-U1sh9 plasmid expressing the modified snRNA U1sh9
was created by cloning the U1 expressing-cassette from a previous pGem-U1sh9
into a pSMD2-ApoE-hAAT backbone containing the AAV8 ITRs sequences for
the subsequent packaging into virion. After restriction digestion the insert and
the backbone plasmid had no overhanging bases at their termini and thus they
were treated with a T4 DNA polymerase (New England Biolabs) in order to
perform a blunt-end cloning. The resulting clones were verified by the sequence
analysis. The virus preparation was carried out in Genethon institute thanks
to the stuff of the Immunology and Liver Gene Transfer section (PI: Federico
Mingozzi), which performed the plasmid triple transfection in Hek293 E4 cells,
the harvest of the cells, the sonication, the PEG precipitation and the rAAV CsCl
purification and dialysis. The rAAV titration to calculate the number of copies
per ml (vg/ml) was performed through qPCR analysis.
2.7.7 Transduction with AAV-U1sh9 in Hek293 stable clones
Hek293 cellular clones were seeded into 12-well plates the day before transduction
at densities of 0.2 ×106 cells/well and maintained in medium DMEM+10% FBS
containing Ponasteron A 1µg/ml. After 24 hours from the initial seeding AAV
34 2. SB Transposon
vectors (AAV-U1sh9 and a negative control represented by an AAV-luciferase)
were added on the cells at different MOI (103, 104, 2 ×104) in a 25ul DMEM-
solution. Cells in each well were incubated at 37◦C overnight with the addition of
500ul DMEM+2%FBS. The day after total RNA was extracted from the cells and
the presence of the hFIX transcript was assessed trough RT-PCR as previously
described.
IN–VIVO STUDY
2.7.8 Generation of vectors
• pT2-ApoE pAAT-SChFIX wt and pT2-ApoE pAAT-SChFIX -2C were cre-
ated by blunt-end subcloning the SC-hFIX cassettes, wt and mutated, from
the previously described pT2 SChFIX wt and pT2 SChFIX -2C to a pAAV–
hFIX backbone containing the human apolipoprotein E (ApoE) control re-
gion followed by the liver specific α1-antitrypsin promoter (hAAT) and the
bovine growth hormone polyadenylation (BGH-pA) signal. The resulting
“ApoE-hAAT promoter–SChFIX-BGH polyA” cassettes were subsequently
obtained by restriction digestion from this plasmid and cloned through
blunt–end junctions between the two ITRs of the pT2-SVNeo backbone.
The FIX–Padua arginine–to–leucine mutation at residue 338 of FIX was
introduced in both hFIX wt and -2C through site–specific mutagenesis by
using QuickChange II XL Site–Directed Mutagenesis Kit (Agilent Tech-
nologies) with the primers R338L F:
5’-GAGCCACATGTCTTCTATCTACAAAGTTCAC-3’
and R338L R
5’-GTGAACTTTGTAGATAGAAGACATGTGGCTC-3’
All the resulting plasmids were verified by the sequence analysis.
• pT2 Empty was created by restriction digestion of the pAAT–SChFIX wt
with ClaI and BstBI enzymes in order to eliminate the SChFIX cassette
between the two ITRs. The backbone was subsequently closed through
ligation of the compatible ends generated by ClaI and BstBI enzymes, thus
creating the pT2 Empty negative control containing the ITRs without the
hFIX expression cassette.
• pT2 cDNA FIX was generated by cloning the ApoE–hAAT–cDNA hFIX–
BGHpA cassette from the pAAV–hFIX plasmid into the ITRs for the SB
transposase. The cassette was obtained by restriction digestion of the
pAAV–hFIX with MscI enzyme and blunt–cloned into the pT2–SVNeo
backbone digested with HindIII restriction enzyme.
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2.7.9 Animal procedures
Animal protocols were approved by the Genethon ethical committee and con-
ducted by certified operators under agreement number CE12–037. Eight–weeks–
old mice C57BL/6 mice were used for in–vivo delivery of plasmids by hydrody-
namic injection of DNA (2ml phosphate buffer saline–PBS) or AAV vectors (0.2ml
in PBS/5% sorbitol) via tail vein injection. While transposon and transposase–
encoding vectors were co–injected at day 0, the AAV vectors have been adminis-
trated at a later stage, with the AAV8–U1sh9 and the AAV8–Luciferase injected
70 days after the first injection. Blood samples were collected from the retro-
orbital plexus at day 0 and every two weeks after first injection.
2.7.10 Measurement of hFIX antigen and mRNA
Human FIX antigen levels in mouse plasma were evaluated by Factor IX Antigen
Kit (Affinity Biologicals) on the mice blood samples according to the manufac-
turer’s recommended protocol. To validate and optimize the assay, a standard
curve was created by adding know amounts of human purified FIX. The sensitiv-
ity threshold of the assay was established at 1ng/ml of hFIX. Depending on the
expected concentrations, mouse plasma samples were diluted from 1:5 to 1:120.
To extract nucleic acids from mouse samples, entire livers were homogenized
by using T10 Ultra Turrax Homogenizer (Hielscher-Ultrasound Technologies) in
PBS-solution. The muscle samples were homogenized in PBS-solution by using
MP FastPrep-24 Tissue and Cell Homogenizer (MP Biomedicals), for 60seconds
at 6.5m/s. To detect hFIX transcripts, total RNA was isolated by using Trizol
Reagent (Invitrogen) and treated with DNase (Ambion-Life Technologies). The
cDNA was generated by RevertAid First Strand cDNA Synthesis Kit (Thermo
Scientific) according to the manufacturer’s recommended protocol. F9 transcript
was detected by PCR with primer hFIX Ex4F and hFIX Ex6R as previously
described.
2.7.11 Assessment of the transgene copy number
To evaluate the transgene copy number the genomic DNA was extracted from
homogenate samples by the MagNA Pure LC Total Nucleic Acid Isolation Kit
(Roche Life Science), according to the manufacturer’s recommended protocol.
Samples were subsequently processed through the MagNA Pure System (Roche)
in 96-well to obtain the gDNA mouse samples. The copy number of the hFIX
transgene that had integrated with the genome of the transgenic animals was
analysed by qPCR with SYBR Green Dye (Bio-Rad). The primers hAAT F
5’-GGCGGGCGACTCAGATC-3’
and hAAT R
5’-GGGAG GCTGCTGGTGAATATT-3’
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were used to amplify 94 bp of the human AAT promoter, while the primers Ttn
F
5’-AAAACGAGCGGTGACATGAGC-3’
and Ttn R
5’-TTC AGTCATGCTAGCGCTCC-3’
were used to amplify 98bp of the mouse TTN gene. The copy number of the
transgene in the examined samples was established by plotting the CT values
obtained on a standard curve, which had been set by the usage of the CT values
for the successive standard dilutions of the plasmid harboring the transgene with
known copy number. The concentration of the plasmid ranged from 5.0 initial
copies to 5×106 final copies. The copy number determined by transgene (hAAT)
specific real-time PCR assay was normalized to the level of one copy control TTN
gene to calculate the final copy number relative to 1000 cells.
2.8 Results
2.8.1 Generation of stable Hek293 clones expressing hu-
man FIX
The creation of an in–vitro model of Haemophilia B caused by splicing mutation
was performed by exploiting the SBTS to obtain stable cell clones expressing
splicing-competent hFIX cassettes (SChFIX), either wt (SChFIX wt) or carrying
the splicing variant FIXex5-2C (SChFIX-2C) in the exon 5 donor splice site [37].
Each splicing-competent construct is based on FIX cDNA region from exon 1
to 4, exon 5 flanked by a splicing-functional region of introns 4 and 5, and the
remaining cDNA from exon 6 to 8. The transposon plasmids are constituted by
the expression-cassettes included between the ITRs recognized by the hyperactive
transposase SB100X for the integration into the genome and placed under the
control of the SV40 strong promoter for the expression of the transgene in cultured
cells (fig.2.5). These vectors have been validated through transient transfection
experiments in Hek293 cells and subsequent RNA analysis and protein assays
(not shown). An additional transposon plasmid containing the coding sequence
for the enhanced green fluorescence protein (eGFP) was used as a marker to select
the transfected cells. The transposase encoding plasmid pSB100X is provided in
trans (fig.2.5).
Preliminary experiments to test the transposase SB100X-mediated transfer
of the SChFIX transgene into the genome were performed in Hek293 cell line.
Cells have been co-transfected with pT2-SChFIX variants together with pT2-
eGFP plasmid at specific molar ratio (5:1), in order to assess the transfection ef-
ficiency and to subsequently select those cells carrying the transgene inserted into
the genome. The plasmid pSB100X expressing the transposase enzyme was co-
delivered in a ratio 1:20 of the total transfecting-DNA. Ten days post-transfection
(to reduce confounding effects of cells carrying plasmids at episomal level) cells
were selected and sorted for the eGFP expression by FACS analysis, and part of
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Figure 2.5: Scheme representing the plasmids used for the generation of Hek293 stable clones
expressing the splicing-competent human FIX expression cassettes. The pT2 plasmids harbor
the SChFIX wt, -2C and eGFP cassettes between the two ITRs recognized by the transposase
enzyme for the integration into the genome. All the expression cassettes are under the control
of the SV40 strong promoter. The transposase is expressed from the pSB100X plasmid
carrying CMV viral promoter.
the recovered eGFP-positive cells were limiting diluted in Petri dishes to obtain
single stable clones expressing eGFP and, probably, hFIX. A negative control was
set up by transfecting Hek293 with the transposon plasmids without the SB100X
encoding-vector. In this case, ten days post-transfection cells were observed by
fluorescence microscopy and, in contrast of those treated with SB100X, no appre-
ciable eGFP signal was detectable. This was further confirmed by FACS analysis
(fig. 2.6).
Figure 2.6: Representative fluorescence-
activated cell sorting (FACS) plots illus-
trating isolation of eGFP-positive Hek293
gated cells. a) Hek293 transfected with pT2
SChFIX wt or -2C in combination with
pT2-eGFP and the pSB100X. b) Hek293
transfected with pT2 SChFIX wt or -2C
in combination with pT2-eGFP without the
pSB100X.
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Approximately two weeks after sorting the single clones were isolated and
propagated for further analysis. The total RNA was extracted from a number
of eGFP-positive Hek293 clones, followed by a specific RT-PCR to detect hFIX
transcript. Noticeably, the expression of hFIX variants was clearly observable
in the majority of the clones after electrophoresis separation of PCR products.
On the contrary, any transcript was detected in the un-transfected cells and
in cells transfected with the transposon plasmids but without the transposase
enzyme (fig.2.7A). As expected from the poor definition of F9 exon 5 [37], even
the wild-type construct produced two transcripts, the full-length one and the
aberrant one showing exon 5 skipping (fig.2.7A lane pT2 SChFIX wt). On the
other hand, cell clones expressing the mutated cassette from pT2 SChFIX -2C
showed almost exclusively the presence of the aberrant form of the hFIX mRNA
lacking exon 5 (fig.2.7A). The quantification of the exon inclusion was performed
by densitometric analysis using ImageJ software and it is established ∼ 93% of
the total transcript for the pT2 SChFIX wt and ∼ 4% for the pT2 SChFIX -
2C (fig.2.7B). The production of secreted hFIX protein in clones expressing the
Figure 2.7: Determination of hFIX expression in eGFP positive Hek293 stable clones. A)
Evaluation of hFIX mRNA through RT-PCR on total RNA extracted from cell clones. The
wt and the aberrant transcripts were resolved through gel electrophoresis on agarose gel 2%.
Negative controls are represented by cells transfected with the transposon plasmids without
the transposase enzyme (∆SB100X) and by cells transfected with the lipofectamine vehicle
alone (mock). B) Histogram reporting the quantification derived from densitometric analysis
of the percentage of exon 5 inclusion. Results are expressed as mean ±SD derived from three
independent experiments.
SChFIX wt cassette has been evaluated by anti hFIX-specific ELISA on culture
medium samples. Protein levels reflected mRNA levels assessed by RT-PCR on
the same samples, varying from ∼3ng/ml to ∼50ng/ml in the positive clones,
indicated as (+) in the figure 2.8a. It is also reported an example of an hFIX
negative clone, indicated as (-), in which the transcripts, as well as the protein,
was not detectable (fig.2.8).
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Figure 2.8: Analysis in Hek293
SChFIX wt clones. a) Evaluation
of hFIX mRNA through RT-PCR
on total RNA extracted from cell
clones. The wt and the aberrant
transcripts were resolved through
gel electrophoresis on agarose gel
2%. b) Histogram reporting hFIX
protein levels in culture medium
assessed by ELISA. Results are ex-
pressed as mean ±SD derived from
three independent experiments.
2.8.2 SB100X activity in–vitro: assessment of the gene
copy number
The transgene copy number was evaluated in a number of Hek293 hFIX stable
clones, wt and -2C, by performing Southern Blot analysis on the gDNA sam-
ples, which were extracted from cells and suitably digested with XbaI restriction
enzyme. This presents a unique cutting site into the SChFIX cassettes, thus per-
mitting the evaluation of the integration pattern profile for each clone analyzed.
A specific hybridization probe was designed to base pair a 450bp region of the in-
tegrated cassettes spanning from hFIX coding sequence exon1 to exon 4 (fig.2.9).
Both DNA from cells expressing the wt and the mutated cassette were run in
Figure 2.9: Scheme representing the structure of the transgenes detected by Southern Blot
analysis. Both the cassettes integrated by the SB100X transposase, the SChFIX wt and -
2C, are 4.2 kb in length, and present an unique recognition site for XbaI restriction enzyme.
The detection probe labeled with alkaline phosphatase is designed to base pair 450 bp spanning
from hFIX cDNA exon1 to exon 4 region.
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the same agarose gel and blotted to the same membrane as the positive control
represented by the linearized pT2 SChFIX plasmid (Ctrl+). The negative control
(Ctrl -) is represented by genomic DNA extracted from untransfected Hek293 cells
(fig.2.10). The southern blot transgene copy number analysis was performed on 4
Figure 2.10: Determination of the copy number of the splicing-competent hFIX transgene in
Hek293 stable clones by genomic Southern Blotting. The genomic DNA (10µg) of Hek293
SChFIXwt and -2C was digested with XbaI restriction enzyme and subjected to electrophore-
sis on a 0.8% agarose gel. The DNA bands were then transferred to a Nylon membrane and
hybridized with an alkaline phosphatase-labeled 450 bp probe generated from pT2 SChFIX
wt plasmid by PCR. Both DNA from cells expressing the wt (lanes 1-4) and the mutated
(lanes 5-8) cassettes were run in the same agarose gel and blotted to the same membrane
as the positive control represented by the linearized pT2 SChFIX plasmid (lane Ctrl+). The
position of molecular weight marker is indicated.
clones for each type of transgene (SChFIX wt and -2C). In each group a negative
control was also loaded (lanes 3 and 7), meaning these are Hek293 eGFP posi-
tive clones non-expressing hFIX. In these lanes there were no detectable bands,
as expected. Vice versa, in the group of samples expressing SChFIX wt (lanes
1-4) some hybridization bands were detected, from a minimum of 2 (lane 2) to a
maximum of 4 (lane 1), thus indicating a multiple copies integration profile. In
the group of samples expressing SChFIX -2C (lanes 5-8) a single copy integration
occurs in sample run on lane 5, because only a band of ∼2kb was detected. In
the other samples integration number varies from 2 to 5 (lanes 6 and 8).
2.9 U1sh9 mediated correction: hFIX mRNA
and protein rescue
To evaluate the capability of the modified snRNA U1sh9 to rescue hFIX mRNA
splicing in the genomic context, Hek293 cells stable expressing the SChFIX -2C
cassette (clones n.1 and 4 chosen as examples) were transiently transfected with
the plasmid encoding the modified U1, pU1-sh9. Moreover, cells were treated with
a modified U1 called U1 FIXwt, designed to perfectly match with exon 5 donor
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splice site [37]. Transfection of hFIX variant expressing cells with either the U1
FIXwt or the U1sh9 resulted in appreciable rescue of correct FIX transcripts, from
0% to ∼20-45%, as revealed from mRNA RT-PCR (fig.2.11A) and densitometric
analysis (fig.2.11B).
Figure 2.11: Treatment of Hek293 SChFIX -2C clones with modified U1sh9. A) Evalua-
tion of hFIX mRNA through RT-PCR on total RNA extracted from cell clones. The wt
and the aberrant transcripts were resolved through gel electrophoresis on agarose gel 2%.
Hek293SChFIX -2C clones 1 and 4 were treated with both U1FIXwt and U1sh9. Mock is
represented by untransfected Hek293 cells. A positive control is represented by hFIX wt
transcript. b) Histogram reporting the quantification of the percentage of exon 5 inclusion.
Results are expressed as mean ±SD derived from three independent experiments.
Moreover, to test the U1sh9-mediated rescue at the protein level an hFIX-
specific ELISA was performed on media from Hek293 clones expressing the SChFIX
-2C cassette, treated or not with the U1sh9. In the untreated cells antigen lev-
els were very low, but after transfection with pU1sh9 a remarkable increase of
secreted hFIX levels (fig.2.12A) in the medium was observable (from ∼3 to ∼45
ng/ml). This increase was paralleled by the relative splicing pattern correction
(fig.2.12B) in which the exon 5 inclusion is stimulated up to ∼45%, as revealed
by densitometric analysis.
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Figure 2.12: Treatment of Hek293 cells expressing SChFIX -2C transgene with modified U1sh9.
A) Evaluation of hFIX mRNA through RT-PCR on total RNA extracted from cells. The
wt and the aberrant transcripts were resolved through gel electrophoresis on agarose gel 2%.
Mock is represented by cells transfected with the lipofectamine vehicle alone. A positive
control is represented by hFIX wt transcript. B) Histogram reporting the quantification of
hFIX protein levels through ELISA assay conducted on the cell medium samples. Results
are expressed as mean ±SD derived from three independent experiments.
2.9.1 Cell transduction with an AAV8-vector expressing
the modified U1sh9
To test the modified ExSpe U1 in–vitro efficacy by delivery through a viral vector,
Hek293 FIX-variant expressing cells were transduced with an AAV8-expressing
U1sh9 under the control of the U1snRNA gene endogenous promoter (fig.2.13).
The infection of stable Hek293 clones was carried out at increasing MOI (from
Figure 2.13: Schematic representation of the expression cassette for the modified U1sh9
snRNA. The coding sequence for the snRNA is under the control of the endogenous pro-
moter of the U1snRNA gene (U1 prom), and inserted between the two ITRs sequence for
the packaging into an AAV8 serotype.
103 to 2× 104). The extraction of total RNA was performed after 72 hours post-
infection, followed by RT-PCR to detect hFIX transcripts. In both cases, i.e. wt
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and the mutated cassette, a dose-dependent rescue of the wt mRNA was obtained
(fig.2.14A). Indeed, the densitometric analysis revealed an increase of the correct
hFIX transcript up to ∼32% for the cells expressing SChFIX -2C and up to ∼85%
for cells expressing SChFIX wt (fig.2.14B). As a further negative control, Hek293-
Figure 2.14: Treatment of Hek293 SChFIXwt and -2C clones with AAV8-U1sh9. A) Evalua-
tion of hFIX mRNA through RT-PCR on total RNA extracted from cell clones. The wt and
the aberrant transcripts were resolved through gel electrophoresis on agarose gel 2%. Both
Hek293SChFIX wt (lanes 1-4) and -2C clones (lanes 5-8) were treated with AAV8 U1sh9
at increasing MOI (from 103 to 2 × 104). Mock is represented by untransduced cells. b)
Histogram reporting the quantification of the percentage of exon 5 inclusion. Results are
expressed as mean ±SD derived from three independent experiments.
variant expressing cells were transduced with an AAV8 expressing Luciferase gene
(AAV8-Luc) at increasing MOI (as previously reported for AAV8-U1sh9). The
extraction of total RNA was performed after 72 hours post-infection, followed by
RT-PCR to detect hFIX transcripts. In this case any effect on splicing pattern
was obtained in comparison with untransduced cells, as expected (fig.2.15).
Figure 2.15: Treatment of Hek293 SChFIXwt and -2C clones with AAV8-Luc. A) Evaluation
of hFIX mRNA through RT-PCR on total RNA extracted from cell clones. The wt and
the aberrant transcripts were resolved through gel electrophoresis on agarose gel 2%. Both
Hek293SChFIX wt and -2C clones were treated with AAV8 Luc at increasing MOI (from
103 to 2× 104). Mock is represented by untransduced cells.
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2.9.2 Generation and validation of the transposon plas-
mids for the creation of mouse models
The creation of mouse models of HB was performed, as for the cellular model,
by designing a panel of trasposon vectors for the SB100X-mediated integration
into the mouse genome. The transposon plasmids consisted of the expression-
cassettes included into the ITRs and placed under the control of the hepato-
specific human apolipoprotein E (ApoE) control region followed by the liver spe-
cific α1-antitrypsin promoter (hAAT) and the bovine growth ormone polyadeny-
lation (BGH-pA) signal (fig.2.16). The expression cassettes are represented by
the splicing-competent hFIX wt and -2C, as well as by a cDNA hFIX positive
control (pT2 cDNA hFIX) and a negative control (pT2 Empty) constituted of
a plasmid carrying the ITRs for the transposase but lacking the expression cas-
sette within them (fig.2.16). These vectors have been validated through transient
Figure 2.16: Scheme representing the plasmids used for the generation of the mouse models
expressing the splicing-competent human FIX expression cassettes. The positive control is
represented by a plasmid expressing the cDNA of hFIX, carrying exon1, an optimized syn-
thetic intron followed by the exon 2-8 remaining part of the coding sequence. The negative
control is represented by an “empty” vector carrying the two ITRs without the interposed
transgene. All the expression cassettes are guided by human ApoE control region followed by
the liver specific hAAT promoter and the BGH-pA signal.
transfection experiments in Huh7 human hepatocarcinoma cells and subsequent
RNA analysis and protein assays. Cells were treated with 3µg of each vector, and
the presence of hFIX mRNA was confirmed by specific RT-PCR (2.17A). Interest-
ingly, Huh7 expressing the mutated cassette from pAAT-SChFIX -2C showed also
the presence of the wt form of the hFIX mRNA, not detectable with the previous
2.9 U1sh9 mediated correction: hFIX mRNA and protein rescue 45
construct (pT2-SChFIX -2C) expressed in Hek293 (see fig.2.7A). The correspond-
ing protein levels were quantified in the medium samples by anti-hFIX ELISA
assay (fig.2.17B), and range from ∼45ng/ml (pAAT-SChFIX -2C) to ∼950ng/ml
(pT2 cDNA FIX). In the negative controls represented by cells treated with pT2
Empty vector and un-transfected cells (mock) no protein level was observable, as
expected (2.17B).
Figure 2.17: Treatment of Huh7 cells with plasmids pT2 cDNA FIX, hFIX wt, -2C and
pT2 Empty optimized for the generation of mouse models. A) Evaluation of hFIX mRNA
through RT-PCR on total RNA extracted from the cells. The wt and the aberrant transcripts
were resolved through gel electrophoresis on agarose gel 2%. Mock is represented by cells
transfected with the lipofectamine vehicle alone. B) Histogram reporting the quantification
of hFIX protein levels through ELISA assay conducted on the cell medium samples. Results
are expressed as mean ±SD derived from three independent experiments.
2.9.3 Generation of the mouse models
The pT2 transposon plasmids optimized for the liver restricted expression of hFIX
were hydrodynamically injected into the tail vein of 8-weeks old C57BL/6J wt
mice (50µg/mouse; n=10 per group) together with the pSB100X transposase-
expressing vector (2µg/mouse). To assess the stable expression of the transgenes
in mouse hepatocytes the plasma levels of circulating hFIX in treated mice were
measured though a hFIX specific ELISA and monitored every 14 days for two
months after the hydrodynamic injection. Positive controls were represented by
mice treated with the cDNA hFIX expressing-cassette and showing stable pro-
tein levels between 100ng/ml (group named cDNA FIX low) and 2µg/ml (group
named cDNA FIX high). Expression at low level was obtained for the SChFIX
cassettes (<10ng/ml after 1 month), especially for the mutated cassette (SChFIX
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-2C) with protein levels below the sensitivity limit of the ELISA at 2 months post-
injection. The negative control is represented by the group co-injected with the
pT2 Empty vector and pSB100X, in which protein levels are no detectable at
each time point (fig.2.18).
Figure 2.18: In–vivo hepatic gene delivery using hyperactive SB100X transposase. The
transposon-containing plasmids (50µg) were co-injected by hydrodynamic gene delivery with
pSB100X (2µg) for the integration into the genome of the hepatocytes. Plasma hFIX con-
centrations were measured (n=10 mice per group) by anti-hFIX ELISA on plasma samples
and analyzed in triplicate each. Mean values of hFIX concentration ± SD are shown for
each time point (every 14 days post-injection).
2.9.4 Assessment of U1sh9 efficacy in–vivo: RNA and
protein analysis
To assess the in-vivo correction efficacy of the U1sh9 on the splicing-defective
hFIX mutant we treated mice with the AAV8-U1sh9 two months after the hy-
drodynamic injection of plasmids. Mice previously injected with pAAT-SChFIX
wt and pAAT-SChFIX -2C were split into two groups (5 mice each) to test the
AAV8-U1sh9 or the AAV8-Luc as negative control. Each AAV vector was deliv-
ered at fixed dose of 5×1010 vg per mouse via tail vein injection. Mice were then
monitored for circulating hFIX levels over a total period of 20 days. However, as
shown in figure 2.19, the FIX antigen levels measured at day 6 and 14 days post
AAV-injection did not indicate any appreciable increase. Mice were then sacri-
ficed to evaluate the effect of the AAV8-U1sh9 delivery on hFIX mRNA splicing
pattern in hepatocytes through RT-PCR analysis in liver tissue samples recov-
ered after the sacrifice of the animals at day 90. As expected, analysis on liver
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Figure 2.19: Timeline of the hFIX levels in mice plasma assessed by ELISA assays. Plasma
hFIX concentrations were measured (n=10 mice per group) by anti-hFIX ELISA on plasma
samples and analyzed in triplicate each. Mean values of hFIX concentration ± SD are shown
for each time point (every 14 days post-hydrodynamic injection, and after 6 and 14 days post
AAV-injection). At day 70 AAV8-tail injection is marked with a red arrow.
samples derived from mice injected with the Empty vector resulted in any de-
tectable transcript (fig.2.20, lanes 1 to 5). On the contrary, analysis on the group
cDNA hFIX wt revealed the presence of hFIX mRNA in all the samples, even
if at different levels (fig.2.20, lanes 11 to 20). Consistently, almost all the mice
injected with the SChFIX cassette wt express hFIX mRNA, with the exception
of one animal in which the transcript is not detectable (fig.2.20, lanes 21 to 30).
Figure 2.20: RNA analyses on the mice liver samples. The Evaluation of hFIX mRNA
through RT-PCR on total RNA extracted from the liver homogenates obtained from mice
group pT2 Empty (lanes 1-5), cDNA hFIX wt (lanes 11-20) and SChFIX wt (lanes 21-30).
The transcript was resolved through gel electrophoresis on agarose gel 2%.
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Most importantly, the RNA analysis on the mice group hydrodynamically
injected with the mutated SChFIX cassette revealed no hFIX expression in the
mice that received AAV8-Luc control vector (fig2.21, lanes 31 to 35), while 3 mice
of 5 treated with AAV8-U1sh9 showed expression of full-length form of the hFIX
mRNA (fig.2.21, lanes 36 to 40). Altogether these data indicated the long-lasting
Figure 2.21: RNA analyses on the mice liver samples. The Evaluation of hFIX mRNA
through RT-PCR on total RNA extracted from the liver homogenates obtained from mice
group pT2 SChFIX -2C (lanes 31-40). The transcript was resolved through gel electrophoresis
on agarose gel 2%.
expression of the mutant hFIX cassette, which points to an integration event, and
the presence of the hFIX pre-mRNA that underwent splicing correction mediated
by the ExSpe U1sh9, although to an extent that was not appreciable at the protein
level.
As a further control to assess liver-restricted expression of the SC-hFIX trans-
gene, we conducted the RT-PCR analysis in muscle triceps samples collected from
mice in all the groups analyzed (cDNA hFIX, SChFIX wt and SChFIX -2C) and
all of them, as for those injected with the pT2 Empty, resulted negative for the
hFIX transcript (data not shown).
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2.9.5 Evaluation of the integration profile: gene copy num-
ber
To unequivocally demonstrate the integration event into the mouse genome me-
diated by the SB100X in–vivo we evaluated the transgene copy number in mouse
liver samples. Therefore, the genomic DNA was extracted from liver homogenate
samples from all mice group treated with pT2 Empty, cDNA FIX, pAAT-SChFIX
wt and pAAT-SChFIX -2C to perform the analysis. The number of copies of the
transgene integrated into the genome was determined by a specific real time PCR
designed to amplify a 94bp region of the human AAT promoter and a reference
genomic DNA of known copy number. The final copy number referred to 1000
cells was determined after normalization to the level of the single-copy control
mouse gene TTN and was reproducible among the all groups (means from ∼17 to
24). The group pT2 Empty negative control showed no copy number, as expected
(fig.2.22).
Figure 2.22: Copy number determination of hFIX cassettes-expressing C57BL/6J mouse hep-
atocytes. The real time specific PCR assay to amplify the human AAT promoter, and used
it together with the single–copy control gene TTN and a reference genomic DNA of known
copy number. Values reported are means±SEM derived from samples analyzed in triplicate.
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2.9.6 Discussion and future plans
The study conducted has permitted to exploit the SBTS as an useful tool to ob-
tain both cellular and animal models of Hemophilia B caused by a specific splicing
mutation, the single point mutation IVS5-2C affecting F9 exon 5 donor splice site,
in order to subsequently test the modified U1-snRNAs corrective approach in a
genomic stable context instead of a transient episomal system, as previously de-
scribed [37]. The in–vitro study performed on the human embryonic kidney 293
cells allowed us to evaluate hFIX transgene expression in a system in which the
background signal is absent because this cells do not express FIX, as revealed
from RT-PCR and ELISA data (fig.2.7). The generation of Hek293 stable clones
expressing the SChFIX variants by taking advantage of the SBTS dual system has
allowed to finely manage the ratio transposon-transposase (in this case 20:1) in
order to avoid unwanted effects like overproduction inhibition (OPI), i.e. elevated
concentration of transposase enzyme inhibit the transposition reaction [42, 92],
and potential cytotoxicity due to residual integration events of transposase ex-
pression vectors that may lead to permanent transposase expression and resulting
in uncontrollable transposition [39]. In our experimental setting the selection of
the cells with the transgene positioned at chromosomal level was carried out by
co-transfecting a second transposon vector expressing eGFP as a reporter. The
usage of two transposon plasmids in each condition instead of a single transposon
carrying the two cassettes in cis was aimed at maximizing the rate of transpo-
sition. Indeed, previous studies indicated that transposition efficiency decreases
at approximately a logarithmic rate as a function of length [42] and that trans-
poson around 6kb retain 50% of the maximal efficiency. Hence, we took advan-
tage of the separate plasmids in order to work with trasposons <5kb in length.
SB100X-mediated transposition occurred efficiently in Hek293 cells, as demon-
strated by the FACS analysis conducted ten days after the initial transfection. As
a matter of fact, just the cells receiving the transposons plasmids together with
the transposase enzymes showed eGFP expression, which was stably maintained
thereafter (fig.2.6), meaning that, once passed the transient episomal phase, the
transgene expression is specifically due to its SB100X-mediated integration into
the genome. The transposase efficiency in–vitro was clearly demonstrated by
performing Southern Blot analysis on the Hek293 stable clones, which showed in
most of the cases a multiple copies integration profile (fig.2.10). Further analyses
at mRNA level demonstrated that Hek293 expressing the hFIX mutant cassette
(SChFIX -2C) displayed the aberrant splicing pattern characterized by exon 5
skipping, and this reflected previous data obtained studying the molecular effect
of this splicing variant through minigene assays [37]. The proper exon defini-
tion and inclusion was partially rescued by transfecting cells with the modified
U1snRNA sh9 (fig.2.11A), able to redirect the spliceosome machinery on the mu-
tated exon 5 donor splice site in order to increase the rate of exon inclusion (up
to ∼45%, see fig.2.11B). This result was paralleled by increase of secreted hFIX
protein in culture medium, as shown by ELISA antigen quantification (fig.2.12).
Moreover, Hek293 cells expressing both the wt hFIX and mutated cassettes were
transduced with an AAV-vector expressing snRNA U1sh9, at increasing MOI,
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thus permitting to assess the dose-dependent rescue of the wt mRNA (fig.2.14).
Interestingly, even the treatment of the cells carrying the SChFIX wt cassette
showed some increase of the correct transcript, as demonstrated by densitomet-
ric analysis (fig.2.14B). The in–vitro study demonstrated the feasibility in the
usage of SBTS in the generation of the model for a splicing mutation and, im-
portantly, the efficacy of the U1sh9 in recovering the proper splicing pattern
in the chromatin context. Altogether these data provided the ground for the
creation of transposon-based mouse models. The SB gene transfer in–vivo was
performed via hydrodynamic injection of plasmids carrying SC-hFIX variants
together with the SB-100X in wild-type C57BL/6 mice. The rationale behind us-
ing wt mice was the availability of nucleic amplification and immunologic assays
able to specifically detect the human FIX expression in the mouse background.
The transposon vectors were specifically designed for optimizing the subsequent
expression of the transgene in mouse liver by taking advantage of the ApoE con-
trol region, the hAAT promoter and a BGHpA sequence. The combination of
these cis-regulatory regions has previously been shown to enhance high and sta-
ble serum hFIX expression in C57BL/6 background after injection in the liver
of mice [63], thus used in this study to guarantee a tissue-specific regulation of
the hFIX transgene. A lower amount of the transposase (2µg of pSB100X) com-
pared to the transposon (50 µg) was hydrodynamically injected in each animal
to avoid an excess of hyperactive SB100X that could diminish the transposition
reaction, consistent with the over-production inhibition. The stable expression
of hFIX was assessed by the measurement of hFIX plasma levels (ELISA) and
by the evaluation of RNA expression in mice hepatocytes through RT-PCR. It is
worth noting the trend of the hFIX expression levels during the entire time pe-
riod of the in-vivo experiment, which is reproducible among all the mice groups
injected, apart from the negative control pT2 Empty (fig.2.18). We can observe
a high spike of expression at day 14 post-injection, followed by a decrease and a
stabilization of the levels measured from day 28 (fig.2.18). Hence it is possible
to speculate about a massive presence of the episomal component maintained for
a few weeks after the hydrodynamic injection, which is probably completely lost
after one month post-injection (fig.2.18). Interestingly, the different possibilities
related to the integration mechanisms can be described by observing the trend in
the hFIX levels for each animal. To simplify, the graph reported below (fig.2.23)
represent all the hFIX measurement relative to the cDNA hFIX positive control
group (n=10).
Noticeably, few mice injected with the cDNA hFIX showed low or no expres-
sion (as example n.17, marked with green symbol) at each time point. In these
few cases we can speculate about an inefficient hydrodynamic procedure, which
is one of the variables in these experimental conditions to be considered. Besides,
some mice (as example n.13, marked with red symbol) showed very high expres-
sion in the supra-physiologic range at day 14 (∼18µg/ml), which remained high
and stable from day 28 for the whole duration of the experiment (∼2.5 µg/ml),
thus supporting good transposition efficiency. Moreover, there is also the case of
an animal showing high expression level at day 14, ∼1µg/ml (see n.19, marked
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Figure 2.23: Timeline of the hFIX levels in mice of the cohort injected with the pT2 cDNA
hFIX, assessed by ELISA assays. Plasma hFIX concentrations were measured (n=10 mice
per group) by anti-hFIX ELISA on plasma samples and analyzed in triplicate each. Mean
values of hFIX concentration ± SD are shown for each time point (every 14 days post-
hydrodynamic injection). The legend reports the number of each mouse injected.
with blue symbol), with a dramatically decrease at day 28 (≤10 ng/ml), main-
tained over time. On the other hand, we observed mice treated with the same
protocol that displayed with very low FIX levels (mice 19, 20), a finding that
could be attributable to a very low transposition rate, or an unsuccessfully com-
bination of the low transposition rate with some unproductive integration sites,
such the delivery of the transgene in some genomic area subjected to epigenetic
silencing-related regulation. As a matter of fact, data from literature have been
shown that SB integration can be considered fairly random into chromosomes,
with roughly 35% of the transposon insertions occurred in transcribed regions
[123]. Importantly, it was possible to observe a good correlation between the
gene copy number in mice hepatocytes and hFIX expression. Indeed, mice show-
ing the higher circulating hFIX levels display also the major copy number (up to
100 copies/1000 cells) corresponding to ∼10% of the entire liver being integrated,
while mice showing low hFIX levels display ∼1-4 copies/1000 cells. Overall, the
mean copy number among the groups pT2 cDNA hFIX, pAAT SChFIX wt and
-2 was reproducible and quantified around 20 copies/1000 cells, meaning that
on average the integration rate in this experimental conditions is ∼2% of the
entire liver (fig.2.22). At a constant integration rate among the groups no corre-
spondence in hFIX levels was observable, in relationship with the nature of the
transgene integrated. The cohort injected with the splicing-competent hFIX wt
exhibit far lower hFIX levels in comparison with the cohort injected with the
cDNA hFIX used as positive control (fig.2.18). Importantly, even if both of them
produce a wt transcript, the splicing-competent cassette composed of the cDNA
with a portion of the introns 4 and 5 (i.e. ∼300bp in proximity of the exon 5,
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to maintain the main splicing regulatory sequences avoiding the too extensive
complete introns) is much less efficient in producing a full-mature mRNA and,
consequently, protein. We can argue that in this condition we are anyway los-
ing some important in-cis regulatory regions, whereas the cDNA hFIX with a
synthetic optimized intron 1 showed high expression efficiency [63, 26, 71]. The
analysis on the RNA pattern in mice liver samples revealed that the treatment
with the ExSPeU1 sh9 delivered by AAV8-vector after around 3 months after the
first injection seems to be effective, because 3 of 5 mice expressing-hFIX mutated
cassette expressed the wt hFIX RNA, while the animal in the same cohort in-
jected with the AAV8-Luciferase control did not show any transcript, neither the
aberrant form lacking exon 5 (fig.2.21). However, any appreciable change in the
hFIX plasma levels were detected after the AAV8-U1sh9 tail vein injection, thus
indicating that the mRNA rescue was not paralleled by an appreciable, in our
experimental setting and with our ELISA system, rescue at the protein levels.
Therefore, our future objective will be the improvement of the experimental
protocol in order to better assess the minigenes rescue in–vivo, i.e. by modulating
the vector doses injected, by exploiting an optimized splicing-competent cassette
to increase the basal hFIX levels and the evaluation of the eventual hepatocellular
toxicity due to ExSPeU1 expression in mouse liver. To magnify the effect at
the protein levels, and to better assess the impact of the ExSpeU1-mediated
correction in mice, we have already inserted into the SCFIX expression cassettes
the F9 R338L Padua mutation that confers a 8-fold increased activity both in–
vitro and in–vivo [28, 38, 50, 82]. Once optimized the protocols in wild-type mice
we plan the creation of HB mouse models for splicing mutations by applying the
approach to F9 knock-out mice. This strategy will permit to assess the U1snRNA-
mediated rescue of FIX antigen and activity levels and, most importantly, the
impact of the treatment on the coagulation cascade efficiency (hFIX levels, aPTT
assays) and the hemorrhagic phenotype (tail-clip assays).
2.10 General conclusions
The experimental activity on disease models such as factor VII deficiency and
haemophilia B enabled us to explore two pioneer approaches for the rescue of gene
expression of coagulation factor, namely the TALE-TFs and the modified snRNA
U1 acting at the transcriptional and post-transcriptional levels, respectively. For
the first time we provided experimental evidence that synthetic TALE-TFs can
efficiently restore promoter activity impaired by disease-causing mutations. This
approach might also suggest an innovative therapeutic approaches for human
diseases in which the increased expression of a compensatory gene would pro-
duce beneficial effects [6]. Worth noting that eTFs could be also exploited to
enhance the efficacy of other well-established correction approaches acting at the
post- transcriptional levels (splicing modulation, ribosome read-through, etc.) by
increasing the amount of the target mRNA. On the other hand, we have success-
fully explored the usage of the SB transposon system, which represented a useful
tool to obtain models of HB caused by splicing mutations. This platform has
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found in the last decade wide application and, because of its versatile activity in
many different tissues, has been explored for ex-vivo and in-vivo gene delivery
[25], but with the associated risks related to genotoxicity and efficient delivery.
Our approach, in which SBTS represents the method for creating a model, has
permitted to conduct the splicing studies and the assessment of the snRNA U1-
mediated therapeutic approach in a genomic physiologic context, both in vitro
and in vivo, thus avoiding the possible confounding effects related to the vec-
tors episomal systems, that do not take into account the chromatin environment.
The proposed approach could be improved and extended to F9 molecular de-
fects other than splicing changes such as nonsense and missense mutations to
create additional HB disease models and permit the investigation of alternative
therapeutic options. It is worth noting that mutations affecting transcription or
splicing are relatively frequent in human disease, particularly in the most severe
cases. Both strategies imply the delivery to the affected cells (hepatocytes for
coagulation factor disorders) of small size cassettes that can be packaged virtu-
ally in any expression vector, thus permitting to overcome limitations related to
vector-mediated delivery of large genes. Moreover, the use of engineered U1 has
the great advantage of maintaining the physiological gene regulation and of res-
cuing gene expression in the affected cells only. Therefore, the results obtained
in these studies as well as the protocols so far developed, could be extended to a
number of other human genetic diseases sharing similar pathogenic mechanisms
and could pave the way for the development of novel therapeutic strategies where
the current ones are difficult or poorly effective.
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